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CHAPTER 1
MITOGEN ACTIVATED PROTEIN KINASES, MAP KINASE PHOSPHATASES
AND CANCER
Introduction
The tight regulation of signaling is an important mechanism that a cell employs to
ensure that messages received both intra- and extracellularly are being interpreted
appropriately, allowing the cell to respond to cues from its environment and make the
changes necessary to continue to survive or to undergo cell death. In cancer, disruption
of normal cell signaling is critical to the continued growth and proliferation of tumor
cells. This can happen in a number of ways, including gaining the ability to sustain
proliferative signaling as well as the ability to resist cell death.1 Sustained proliferative
signaling often takes the form of increased growth factor activity. This increase can
contribute to the cell’s ability to resist cell death, but often the cell is also able to
downregulate factors that would lead to apoptosis. One group of signaling molecules
with close ties to cancer that contains members involved in both cell growth and cell
death is the Mitogen Activated Protein Kinase (MAPK) family.
Mitogen Activated Protein Kinase Signaling: Overview
There are three major branches of MAPK signaling in mammalian cells: the
extracellular signal regulated kinases (ERK), the c-Jun N-terminal kinases (JNK) and the
p38 MAP Kinases (Fig. 1).

ERKs are activated by growth factors and generally

contribute to cell growth. JNK and the p38 MAP kinases can be activated by growth
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factors, cytokines and cellular stress. The JNK and p38 pathways can be involved in both
cell growth and cell death, depending on the cellular context.2-6 All three branches follow
a general signaling paradigm in which a stimulus is received at the cell membrane and is
transmitted through upstream adaptor molecules and enzymes to a MAP kinase kinase
kinase (MKKK). ERK has only one MKKK, Raf.2,6,7 B-Raf has been shown to be the
predominant isoform involved in activating MEK.2 JNK and p38 share several MKKKs,
including ASK1 (Apoptosis Signal Regulating Kinase 1), MLK2 (Mixed Lineage Kinase
2), MLK3 (Mixed Lineage Kinase 3), TAK1 (TGF-β-activating Kinase 1) and DLK
(Dual Leucine Zipper Bearing Kinase). Additional JNK MKKKs include MEKK1 (MEK
Kinase 1), MEKK4 (MEK Kinase 4), MLK1 (Mixed Lineage Kinase 1), MLK4 (Mixed
Lineage Kinase 4) and ZAK (Zipper Sterile- Motif Kinase).2,6,7 Phosphorylation of
MKKK, in turn, allows for the phosphorylation of specific MAP kinase kinases (MKK).
MEK activates ERK, MKK4/7 activates JNK and MKK3/6 activates p38.2,6,7 In order to
be activated, each MAPK must be dually phosphorylated on threonine and tyrosine
residues in a TXY motif.5,6,8,9 Once activated, the MAPKs go on to phosphorylate a wide
variety of transcription factors, enabling them to affect the transcription of their
respective target genes.7
There are multiple isoforms that make up each branch of the MAP Kinase family:
six ERKs, three JNKs and four p38s. The ERK branch is made up of ERK1-5 and
ERK7/8.2 ERK1 and ERK2 are the best characterized and considered the “classical”
members of the family. These two kinases share an 83% sequence homology and are
regulated by many of the same factors.2 The amino acid activation motif for ERK1 and
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ERK2 is T-E-Y. ERK3 and ERK4 are unique in that their activation motif is S-E-G,
suggesting that these two kinases do not require dual phosphorylation for activation.
Little else is known about either of these kinases.2 ERK5 has the same activation motif
as ERK1 and ERK2 and has been shown to regulate cell survival and proliferation.7
Along with ERK3 and ERK4, ERK7/8 is considered an atypical MAPK. It has a T-E-Y
activation motif similar to the conventional MAPKs, ERK1/2 and ERK5, but it is unique
in that it has been shown to be constitutively phosphorylated, perhaps via
autophosphorylation.7 There are three different JNK isoforms, JNK1, JNK2 and JNK3.
These kinases have a T-P-Y activation motif.2 JNK1 and JNK2 are broadly expressed,
with JNK3 displaying a more restricted tissue distribution.7 JNK1 and JNK2 are known
to regulate the cell cycle via its phosphorylation of c-Jun, which forms part of the AP-1
transcription factor. These kinases also play an important role in regulating apoptosis in
response to cell stress.7 The p38 branch of the MAP Kinase family has four members,
p38α, p38β, p38γ and p38δ. p38α is the predominant isoform.7 The activation motif for
p38 is T-G-Y. The p38 MAPKs are known to be strongly activated by cell stress and
inflammatory cytokines and to negatively regulate the cell cycle.7
MAP Kinase Phosphatases: Overview
Due to the wide ranging effects of MAP Kinase activation, it is important that
there are mechanisms in place to attenuate their signals. This is partially accomplished
by a family of dual specificity phosphatases (DUSPs) called MAP kinase phosphatases
(MKPs), which are the endogenous negative regulators of MAPKs (Fig. 1).
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Figure 1. MAP kinase signaling. The three branches of the MAP kinase signaling
family in mammalian cells are activated by stimuli at the cell surface. MAP kinase kinase
kinases relay the signal to MAP kinase kinases, which activate ERK, JNK, and p38. The
phosphorylation of their respective targets completes the cascade. MAP kinase
phosphatases are endogenous negative regulators of MAP kinases. MKPs attenuate the
signal by dephosphorylation and prevent MAPKs from carrying out their cellular
functions6. (Figure reproduced from Haagenson, K. K. & Wu, G. S. The role of MAP
kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer
Metastasis Rev 29, 143-149, (2010).)
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MKPs are dual specificity threonine-tyrosine phosphatases that recognize the TXY motif
present in the MAPKs.8 There are eleven MKP family members, which can be grouped
by subcellular localization and substrate specificity (Table 1). There are four nuclear
MKPs: MKP-1 (DUSP1), MKP-2 (DUSP4), PAC-1 (Phosphatase of Activated Cells,
DUSP2) and hVH3 (Human VH-1-like Clone 3, DUSP5). MKP-1 has been reported to
dephosphorylate ERK1/2, JNK1/2 and p38α10,11, but a subsequent study, in which MKP1 was conditionally expressed from the human metallothionein IIa promoter in U937
cells, revealed a slightly more complex picture.

Conditional expression of MKP-1

confirmed that the phosphatase could inhibit ERK, JNK and p38, but when MKP-1 levels
were titrated, JNK and p38 were more sensitive to MKP-1 inhibition than ERK,
suggesting that these MAPKs are the preferred substrates of MKP-1.12 MKP-2 has also
been shown to dephosphorylate each of the three MAPKs at high concentrations, but
when transfected into cells under conditions more closely resembling physiological levels
it was shown to be active toward ERK and JNK, but showed little activity toward p38.11
PAC-1 shows specificity for ERK and p38, while hVH3 is primarily an ERK specific
phosphatase.2,5,6,8 A second group of MAPKs containing MKP-3 (DUSP6), MKP-4
(DUSP9) and MKP-X, is found in the cytoplasm. With the exception of MKP-4, which
demonstrates activity toward both ERK and p38, this group exclusively targets
ERKs.2,5,6,8,13 The third group of MKPs can claim MKP-5 (DUSP10), MKP-7 (DUSP
16) and hVH5 (DUSP8) as its members and can be found in both the nucleus and the
cytoplasm. These three MKPs dephosphorylate JNK and p38.2,5,6,8,13,14 Although the
MKPs might appear to be functionally redundant, they are known to display restricted
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Subcellular

Substrate

Location

Specificity

MKP-1 (DUSP-1)

Nucleus

JNK, p38 > ERK

MKP-2 (DUSP-4)

Nucleus

ERK, JNK > p38

MKP-3 (DUSP-6)

Cytoplasm

ERK

MKP-4 (DUSP-9)

Cytoplasm

ERK, p38

MKP-5 (DUSP-10)

Nucleus/Cytoplasm

JNK, p38

MKP-7 (DUSP-16)

Nucleus/Cytoplasm

JNK, p38

MKP-X (DUSP-7)

Cytoplasm

ERK

PAC-1 (DUSP-2)

Nucleus

ERK, p38

hVH3 (DUSP-5)

Nucleus

ERK

hVH5 (DUSP-8)

Nucleus/Cytoplasm

JNK, p38

MKP (DUSP)

Table 1. MAP Kinase phosphatase family members. The members of the MKP
family, along with their subcellular localization and substrate specificity.
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tissue expression.2,8,14
The final member of the MKP family is MK-STYX, which is an inactive
phosphatase. It is grouped with the other MKPs based on structural similarity.5 The
predominant features used to classify phosphatases as MKPs (Fig. 2) are the presence of
a C-terminal catalytic domain and an N-terminal domain that contains two regions of
sequence homology to the catalytic domain of the cdc25 phosphatase.5,6,13,15 Each of the
MKPs has a kinase interaction motif between the two cdc25 homology domains. MKP-1,
hVH3 and MKP-7 also have nuclear localization sequences. The three cytoplasmic
MKPs, along with MKP-7 and hVH5, contain nuclear export sequences. MKP-7 and
hVH5 also have PEST domains.13 The active sites of the MKPs contain a catalytically
critical cysteine residue present in a signature phosphatase motif: -HCXXXXXR-. These
residues work together with a conserved aspartate to facilitate the dephosphorylation of
the MAPKs.16 A substrate induced activation model has been proposed for MKPs in
which binding to the MAPK via a MAPK binding domain alters the interaction between
the binding domain and the dual specificity phosphatase domain, which contains the
active site.

This conformational change positions the catalytic domain for optimal

dephosphorylation of the MAPKs16 and the structure/function relationship enables
precise termination of MAPK signaling. Thus, the interplay between MAPKs and MKPs
helps to maintain the delicate balance of signals present in the cell and allows it to
respond to changing environmental cues. The inactivation of MKPs is not an area that
has been widely studied. It has been shown that MKP-117 and MKP-218,19 are able to be
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Figure 2. Structural domains of the MKPs. “Classification, domain structure
and phylogenetic analysis of the dual-specificity MAPK phosphatases. (A)
Domain structures of the ten catalytically active DUSP proteins and MK-STYX.
In addition to the N-terminal non-catalytic domain containing the
Cdc25/rhodanese-homology region and the catalytic site, the positions of the
conserved kinase interaction motif (KIM), nuclear localization signals (NLS),
nuclear export signals (NES) and PEST sequences are indicated. The three
subgroups revealed by the phylogenetic analysis are indicated by the background
color. (B) DUSP sequence analysis. Human DUSP amino acid sequences were
sligned using CLUSTALW and a phylogenetic tree was genereated. The three
subgroups of DUSP proteins together with defining properties are indicated by
the colored ovals.” Figure reproduced with permission from Dickinson, RJ and
Keyse, SM. J Cell Sci. 2006 Nov 15;119(Pt 22):4607-15.
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degraded by the proteasome.

Proteasomal degradation of MKP-1 is enhanced by

phosphorylation on Ser 296 and Ser 323.20 Conversely, phosphorylation of Ser 359 and
Ser 364 protects MKP-1 from degradation.17 Similarly, phosphorylation of Ser 386 and
Ser 391 of MKP-2 stabilizes the protein and protects it from proteasome-mediated
degradation.19 In addition to degradation, it has been shown that reactive oxygen species
are able to oxidize the cysteine residue in the catalytic site, leading to the inactivation of
phosphatase activity. This inactivation can either be reversible or irreversible, depending
on how many oxygen molecules react with the cysteine residue. Formation of sulfenic
acid via the addition of one oxygen results in reversible inhibition of phosphatase
activity, whereas as the formation of sulfinic (two oxygens) or sulfonic (three oxygens)
acid resulted in irreversible inhibition of phosphatase activity.21
MAP Kinases and Breast Cancer
In the United States, breast cancer is the most commonly diagnosed form of
cancer in women (not counting skin malignancies), with an estimated 227,000 new cases
in 2012. Additionally, approximately 40,000 women are projected to die from their
disease, making breast cancer the second-leading cause of cancer death among women
behind lung cancer.25 Breast cancer is a heterogeneous disease made up of several
different subtypes that have been identified through analysis of gene expression
patterns.26
The broadest classification of breast tumors is based on the expression of the
estrogen receptor (ER), more specifically the expression of ER-. Approximately 70%
of human breast tumors are classified as positive for ER- expression.27,28 The ER is a
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nuclear steroid hormone receptor whose structure is critical for understanding its
function. The N-terminal A/B domain contains activation function 1 (AF-1) which is
responsible for the ligand independent activation of the receptor via protein-protein
interactions and for the transcriptional activation of target genes. The C domain is the ER
DNA binding domain which is also involved in receptor dimerization.29 The D domain is
a hinge region. The E domain includes the ligand binding domain, which contains ligand
dependent activation function 2 (AF-2). In addition to ligand binding, this domain is
involved in nuclear translocation, receptor dimerization and target gene expression.29
The F domain is involved in the recruitment of co-activators. When ligand binds to the
receptor, helix 12, located in the E domain, moves over the ligand binding pocket and
creates a surface for co-activator binding. When the ER is bound to an antagonist, helix
12 instead occupies a hydrophobic groove created by helices 3, 4 and 5. This eliminates
the ability of the receptor to interact with co-activators.29
When ligand is bound to the receptor, the ER forms a dimer with another ER
molecule and translocates to the nucleus where it is able to bind to DNA via estrogen
response elements (EREs) present in the promoters of its target genes (Fig. 3). The ERE
consensus sequence is 5’-GGTCAnnnTGACC-3’. Many genes regulated by estrogen,
however, contain imperfect, non-palindromic ER binding sites.30 Additionally, it has
been shown that an ER- dimer can bind to a half site if stabilized by protein-protein
interactions with another transcription factor such as Sp-1.30 The ability of the ER to
regulate transcription of its target genes by binding to consensus sequences and imperfect
EREs, as well as its ability to interact with other transcription factors and co-activators
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Figure 3. Estrogen and Tamoxifen Mechanisms of Action. Estrogen binding to the
estrogen receptor causes its dimerization, which is followed by translocation to the
nucleus and DNA binding, followed by the recruitment of co-activators and transcription
of the target gene. Tamoxifen competes with estrogen to bind to the receptor, preventing
co-activator recruitment and transcription of target genes.
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present in the cell, demonstrates that the context in which this signaling occurs is very
important in determining its outcome. Another example of how the context of cell
signaling influences the transcription of estrogen regulated genes is through
phosphorylation of the estrogen receptor. These post-translational modifications are
carried out by different kinases and modify ER activity.27,29 Several sites have been
identified that can be phosphorylated by ERK, including Ser 102, Ser 104, Ser 106, Ser
118, Ser 167 and Thr 311.27 Of these sites, phosphorylated Ser 104/106, Ser 118 and Ser
167 have been suggested to have a connection to tamoxifen response in breast cancer.
It has been shown that many breast cancers contain an increased proportion of
cells with activated ERK.22 A 1997 study by Sivaraman et al. assessed the activity of
ERK in 37 breast tissue samples, 11 of which were determined to be breast carcinomas.
Each of the breast tumors showed increased ERK activity, measured by an in vitro kinase
assay, compared to samples taken from patients with benign breast disease. Subsequent
analysis of the breast carcinomas showed that ERK mRNA expression was elevated in
malignant epithelial cells, but not in stromal cells in both the primary tumors, as well as
in lymph node metastases, suggesting that the overexpression and increased activity of
ERK might play a role in tumor initiation and progression.23
Overexpression of both p38 and JNK1 has also been noted in primary breast
tumors. An examination of 14 breast tumor samples paired with non-malignant breast
tissue samples from the same patients revealed that p38 expression and activity were both
increased three-fold in the malignant tissues.
expression was also observed.24

A similar three-fold increase in JNK
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MAP Kinases and Endocrine Therapy Resistance
For women diagnosed with ER-positive breast cancer, first line therapy involves
treatment with tamoxifen, a selective estrogen receptor modulator that mimics the
binding of estrogen to the ER (Fig. 3). In breast tissue, tamoxifen is known to act as an
antagonist. When tamoxifen is bound to ER, co-activators are unable to bind, repressing
the transcription of estrogen responsive genes. In bone and uterine tissue, however,
tamoxifen has been shown to act as an agonist and has been associated with an increased
risk of endometrial cancer. This effect must be taken into consideration when using the
drug in the clinic. When used in an adjuvant setting, tamoxifen treatment reduces the
odds of developing recurrent disease by approximately 40 to 50%.31 Approximately 30
to 50% of patients presenting with metastatic disease will experience temporary
remissions while on tamoxifen therapy.31,32 However, almost all of these women will go
on to develop recurrent disease that is resistant to tamoxifen treatment. This fact makes it
clear that tamoxifen resistance is a major problem in the clinical setting and underscores
the need to establish biomarkers to identify patients who will benefit the most from TAM
therapy, as well as for development of novel drug targets.
Due to the heterogeneous nature of breast cancers and the complexity of signaling
that occurs in tumors, it is not realistic to expect that a single mechanism would be
identified as the cause of resistance in patients. Therefore, it is important to continue to
explore all possible causes in an attempt to determine which patients will experience the
greatest benefit from tamoxifen treatment. Even in the presence of tamoxifen, it is still
possible to have activation of estrogen responsive genes (Fig. 4). One such mechanism is
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through the hypersensitization of the ER to ligand binding.

Following estrogen

deprivation, the receptor is able to become activated in response to much lower
concentrations of estrogen compared to conditions when ligand is present in abundance.
Many molecular mechanisms of tamoxifen resistance have been suggested, including, but
not limited to, several that involve MAP Kinase signaling.

In another scenario,

tamoxifen is able to act as an agonist via ER interactions with transcription factors such
as AP-1 or Sp-1. For example, AP-1, which is a downstream target of MAPK signaling,
binds to its response element and is able to crosstalk with the tamoxifen-bound ER,
changing the context for the regulation of its target genes. Yet another mechanism
involves the ligand independent activation of the ER. As noted earlier, ERK is able to
directly phosphorylate several residues on the estrogen receptor. Phosphorylation of Ser
118, which is located in the ligand independent AF-1 portion of the ER A/B domain, is
perhaps the best characterized, but most enigmatic of the sites targeted by ERK. A 2006
study done by Sarwar et al used immunohistochemistry to examine Ser 118
phosphorylation in 301 breast tumor biopsies and found that 83% of the tumors that were
positive for ER- were also positive for phospho-Ser 118. Additionally, there was a
correlation between positive Ser 118 phosphorylation and low tumor grade, indicating
that phospho-Ser 118 might be associated with more favorable prognosis.33 When
phosphorylation of Ser 118 was examined in a smaller group of patients (n=21) that

15

Figure 4. Regulation of E2 responsive genes in the presence of tamoxifen. Following
estrogen deprivation, the estrogen receptor becomes responsive to lower concentrations
of ligand than when ligand was plentiful. This is called hypersensitization. Ligand
independent activation of the receptor can occur when kinases such as ERK
phosphorylate residues in the ER, such as Ser 118, in AF-1 of the A/B domain.
Tamoxifen bound ER binds to other transcription factors, like AP-1 or SP-1, using them
as a scaffold to drive the transcription of genes that were not previously transcriptionally
regulated by ER.
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had relapsed while on tamoxifen, a statistically significant difference in the levels of
phospho-Ser 118 pre- and post-treatment was observed. Eleven patients showed an
increase in Ser 118 phosphorylation post-treatment. In vitro studies, however, have
shown increased phosphorylation of Ser 118 and ERK activity in tamoxifen resistant
MCF7 cells, derived by long term culture in the presence of tamoxifen, compared to their
tamoxifen sensitive MCF7 counterparts.33 The authors suggest that these results show
that Ser 118 phosphorylation in breast tumors is not predictive of treatment failure as
might be inferred from their in vitro results. They do, however, acknowledge that the
change in Ser 118 phosphorylation post-treatment might indicate a role in the emergence
of resistance.33 It has also been demonstrated that ERK phosphorylation and its increased
activity are associated with endocrine therapy resistance and decreased survival in breast
cancer patients.34 Taken together these data seem to suggest that phosphorylation of Ser
118 in the estrogen receptor is associated with favorable prognosis prior to tamoxifen
treatment, but unfavorable prognosis after tamoxifen resistance is acquired.35 The other
phosphorylation sites shown to be associated with tamoxifen response and targeted by
ERK are Ser 104/106 and Ser 167. Phosphorylation of Ser 104/106 leads to ligand
independent activation of the receptor and agonistic activity of tamoxifen.27
Phosphorylation of Ser 167 increases binding of the ER to DNA and enhances coactivator binding in the presence of estrogen. In vitro it has been shown that Ser 167
phosphorylation reduces sensitivity to tamoxifen.27

However, similar to Ser 118

phosphorylation, conflicting clinical data make it difficult to assess what the true
contribution of this modification is to tamoxifen resistance.

In addition to
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phosphorylation by ERK, Ser 167 is phosphorylated by Akt. Akt activity has been
associated with decreased overall survival in breast cancer. In metastatic breast cancer,
however, phospho-Ser 167 is associated with longer survival following relapse.27
Overexpression of HER2, which has been shown to lead to the activation of ERK
in breast tumor cell lines, has also been suggested as a mechanism of tamoxifen
resistance in breast cancer.

It has been observed that tamoxifen treatment slightly

increases the expression of both EGFR and HER2 and that the expression of these
molecules was greatly elevated in resistant tumors.36

Clinical studies showed that

patients whose tumors overexpress these two molecules were less likely to benefit from
tamoxifen treatment. A few different underlying mechanisms have been suggested for
the contribution of EGFR and/or HER2 overexpression to tamoxifen resistance.36 In a
study done by Massarweh et al, elevated levels of EGFR in MCF7 xenografts were
associated with acquired tamoxifen resistance, but it was shown that genes classically
regulated by estrogen were repressed in the presence of tamoxifen, suggesting that tumor
growth in this model was through non-genomic ER-mediated activation of EGFR.
Similar results were seen in tumors engineered to overexpress HER2.36 It is thought that
this non-genomic activation might be carried out by a small fraction of ER that remains
near the plasma membrane.36 Strong correlations amongst HER2, ERK and MKP-1
protein expression have also been demonstrated. Following activation of the MAPK
pathway, it is thought that strong, sustained ERK activity leads to cell cycle arrest via
senescence or differentiation.
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Based on the hyperactivation of MAPK signaling in tamoxifen resistant tumors, it
has been suggested that the inhibition of this pathway might restore tamoxifen sensitivity
in breast cancer cells. To this end, it has been shown that exogenous inhibitors of HER2
signaling are able to partially restore sensitivity to anti-estrogens. MCF7 cells engineered
to overexpress HER2 were treated with AG1478. This treatment abolished HER2 and
MAPK phosphorylation, reduced ERE driven luciferase reporter activity in the presence
of tamoxifen and showed inhibition of colony formation at levels similar to vector control
treated cells, which was 80% compared to untreated controls.37 Another similar study
done by Ghayad et al, showed that inhibition of the ERK pathway using the MEK
inhibitor PD98059 and the PI3K/Akt pathway with the inhibitor LY294002 was able to
restore tamoxifen sensitivity in cell line models of acquired tamoxifen resistance. In their
model of endocrine resistance, which was also initially derived from MCF7 cells, two
independently selected clones developed concomitant activation of both the MAPK and
PI3K/Akt pathways. These clones also showed increased phosphorylation of Ser 118 and
Ser 167 of the ER. A combination treatment of tamoxifen and PD98059 completely
reversed the tamoxifen resistant phenotype seen in these clones, shown by a reduction in
BrdU incorporation and an increase in annexin V staining, which is an indicator of
apoptosis, in comparison to vehicle treated control cells. ER Ser 118 phosphorylation
was also reduced. Similar results were seen with the combination of tamoxifen and
LY294002.

When the clones were subjected to treatment with combinations of

PD98059, LY294002 and tamoxifen, interestingly, one clone was most sensitive to
inhibition by tamoxifen and PD98059 and the other was most sensitive to tamoxifen and
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LY294002. The combination of all three drugs inhibited cell proliferation in a manner
similar to the optimal inhibitor in each case. Since these clones were selected through the
same process, the authors suggest that this model reflects the heterogeneity observed in
breast tumors and conclude that inhibiting both the MAP Kinase and PI3K/Akt pathways
would be the most effective treatment strategy in a clinical setting.38
The previous data show that an increase in ERK signaling is a common event in
breast cancer tamoxifen resistance and that inhibition of this pathway using small
molecule inhibitors might be an effective approach to restore sensitivity. This begs the
question as to what role MAP Kinase phosphatases, the endogenous negative regulators
of MAPKs, play in this process.

While very little is currently known about the

connection between MKPs and tamoxifen response, MKP expression has been shown to
be altered in a number of cancers and MKP-1 has been linked to resistance to a number
of chemotherapeutic agents.
MAP Kinase Phosphatases and Cancer
To date, six of the eleven MKP family members, MKP-1, MKP-2, MKP-3, MKP4, MKP-7 and PAC-1, have been shown to exhibit altered expression in a variety of
human malignancies (Table 2). Most of what is known pertains to MKP-1, since it is the
founding member and best characterized of the MKP family, but to gain perspective on
what is known about the overall picture of MKP signaling in cancer cells, it is important
to briefly survey the contribution of the other MKPs to cancer development and
progression.
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Phosphatase

Cancer Type

MKP-1

Bladder, Breast, Colon, Lung,
Ovarian, Prostate

MKP-2

Breast, Liver, Ovarian, Pancreatic,
Glioma

MKP-3

Breast, Ovarian, Pancreatic

MKP-4
MKP-7
PAC-1

Skin
Leukemia
Ovarian

Change in Expression
Downregulated in Bladder (M)
Upregulated in Breast (M, P)
Downregulated in Colon (M)
Upregulated in Lung (M, P)
Upregulated in Ovarian (M, P)
Downregulated in Prostate (M, P)
Upregulated in Breast (P)
Upregulated in Liver (M)
Downregulated in Ovarian (M)
Upregulated in Pancreatic (P)
Downregulated in Glioma (M)
Upregulated in Breast (M)
Downregulated in Ovarian (M, P)
Downregulated in Pancreatic (M, P)
Downregulated (M, P)
Downregulated (M)
Upregulated (M)

Table 2. Alterations of MKP Expression in Human Cancer. M=change in mRNA
expression. P=change in protein expression. References: MKP-13,4,8,9,14,24,39-42, MKP29,24,43-45, MKP-39,46-49, MKP-450, MKP-751,52, PAC-153
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PAC-1, MKP-3, MKP-4, and MKP-7 and Cancer
PAC-1, MKP-3, MKP-4 and MKP-7 have been shown to play a role in various
cancer types. PAC-1, a nuclear phosphatase with activity directed toward ERK and p38,
has been shown to be associated with overall survival in ovarian cancer. In a study of
thirty-nine patient samples from serous ovarian tumors, high PAC-1 mRNA expression
levels correlated with worse overall survival compared with those patients whose tumors
expressed low PAC-1 levels.5,53 MKP-3, a cytoplasmic, ERK specific phosphatase, is
connected to pancreatic, ovarian and breast cancer. The loss of MKP-3 expression in
pancreatic cancer is associated with disease progression.

Compared to in situ

carcinomas, a decrease in expression was observed in primary invasive pancreatic tumor
tissues46. Another study revealed that many precursor lesions lacking MKP-3 expression
harbored K-ras mutations.5,47 Similar losses of expression have been observed in ovarian
cancer cell lines. MKP-3 protein expression was shown to be much lower in these cell
lines compared to normal samples and immortalized cell lines.5,49 MKP-4 is an ERK and
p38 specific phosphatase located in the cytoplasm. Loss of MKP-4 expression has been
connected to skin cancer development. Reintroduction of MKP-4 in malignant cells led
to microtubule disruption and in vivo tumor suppression.5,50 MKP-7, a JNK and p38
phosphatase found in both the nucleus and the cytoplasm, has been associated with
leukemia. Overexpression of MKP-7 in Rat-1 fibroblasts transformed with BCR-ABL
showed a reduction in JNK activation and a decreased ability to be transformed both in
vitro and in vivo.5,52

Additionally, downregulation of MKP-7 by miR-24, whose

expression is induced by both AML-1 and AML1-ETO, has been linked to development
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of acute myeloid leukemia. Decreased MKP-7 led to increased phosphorylation of JNK
and p38, which stimulated myeloid cell growth and inhibited differentiation.5,51
MKP-2 and Cancer
MKP-2, which is a nuclear phosphatase that primarily targets ERK and JNK, has
shown altered expression in liver, pancreatic, ovarian and breast cancers. MKP-2 was
first identified by Misra-Press et al in 1994.54 The authors of this study demonstrated that
MKP-2 is expressed in a wide variety of rat tissues in a profile that is overlapping yet
distinct from MKP-1. They also suggested that this differential expression combined
with the unique N-terminal sequences of the two phosphatases indicate distinct functional
roles for each protein.54 In a study that investigated hepatocarcinogenesis and hepatoma,
no expression of MKP-2 could be detected in normal liver, but was present in three out of
five primary hepatomas studied.5,43 MKP-2 mRNA levels were also elevated in ascites
hepatoma cell lines compared to normal liver.5,43 The authors of this study suggest that
MKP-2 expression might be used as a tumor marker in the liver.5,43 MKP-2 has also been
linked to the suppression of ERK activity in pancreatic cancer cells harboring K-ras
mutations.44 The expression of MKP-2 in pancreatic tumor cell lines correlated with
MEK expression. When BxPC-3 and Capan-1 cells were treated with MEK inhibitor
PD98059, MKP-2 expression was markedly decreased.5,44 Subsequent work examining
post-translational modifications of MKP-2 showed that ERK is able to phosphorylate
MKP-2 on Ser 386 and Ser 391, which stabilizes the protein and forms a feedback loop
for the regulation of ERK signaling. Inhibition of ERK activity with MEK inhibitor
U0126 abolished MKP-2 phosphorylation and co-treatment with the proteasome inhibitor
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MG132 showed that in the absence of this phosphorylation, MKP-2 protein is degraded
by the proteasome.19 Additionally, MKP-2 has been shown to be overexpressed in serous
borderline tumors of the ovary, but expression was lost in serous carcinomas.9 MKP-2 is
co-expressed with MKP-1 in breast cancer.24
MKP-1 and Cancer
MKP-1 is a nuclear phosphatase that is able to dephosphorylate all three MAPKs,
with preference for JNK and p38 as substrates compared to ERK. It is unclear what the
precise physiological function of MKP-1 is in normal tissues, as MKP-1 knockout mice
show no obvious phenotype.2 Other studies seem to indicate, however, that MKP-1 may
be involved in the inhibition of pro-inflammatory signaling.13 MKP-1 has also been
identified as a transcriptional target of p53, suggesting it may play a role in cell cycle
control.55 The second intron of MKP-1 contains a p53 binding site. This study also
showed that when MKP-1 phosphatase activity was inhibited using vanadate, a general
phosphatase inhibitor, induction of p53-mediated G1 arrest in response to growth factor
stimuli was compromised. p53 also regulates MKP-1 protein expression in response to
oxidative stress in colon cancer cells.56 In addition to colon cancer, MKP-1 expression
has been shown to be altered in prostate, bladder, ovarian, non-small cell lung and breast
cancers.5,6,8 In colon, bladder and prostate cancer, MKP-1 is overexpressed in the early
stages of disease, but expression seems to be lost as the disease progresses.5,9 Microarray
analysis of colorectal tumor samples from nine patients participating in a Phase I/II
clinical trial examining a treatment regimen consisting of bevacizumab, a VEGF
inhibitor, and radiation therapy revealed that MKP-1 mRNA expression was significantly
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downregulated in all samples after treatment. The size of decrease, however, varied from
patient to patient.5,40 The authors suggest that this decrease is due to the reduction in
tumor proliferation following treatment.40 MKP-1 expression has been linked to clinical
outcome in ovarian cancer, where increased expression correlated with shorter
progression-free survival.5,9 In a separate study, moderate to strong MKP-1 expression
was seen in 57.6% of invasive primary ovarian tumors (n=66).5,41 In lung cancer, when
compared to normal tissue samples, MKP-1 expression was increased in non-small cell
lung cancer tissue samples. In this study, high MKP-1 expression levels independently
predicted better survival outcomes.8

In a small clinical study, tumor samples were

obtained from 14 breast cancer patients and examined for expression of the three
MAPKs. This study showed that ERK, JNK and p38 were all upregulated in malignant
versus non-malignant tissue samples. The study also looked at JNK activity and found
that it was 30% lower in malignant tissue than in normal tissue. Further investigation
into the disparity between higher protein expression level and reduced activity level of
JNK revealed that MKP-1, along with MKP-2, displayed increased expression in the
malignant tissue. The authors suggest this increase in MKP expression as a possible
mechanism for the decrease in JNK activity.5,24 Since a reduction in JNK activity may
play a role in reducing the effectiveness of chemotherapy drugs, it is possible that
downregulating MKP-1 expression might be a novel way to combat chemotherapy
resistance.5
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MKP-3, MKP-1 and Breast Cancer Treatment Resistance
MKP-3 and Tamoxifen Resistance
MKP-3 is the only MKP so far to be directly studied in relation to tamoxifen
resistance in breast cancer.

A study done by Cui et al analyzed MKP-3 mRNA

expression in nine tumors, four of which were tamoxifen sensitive and five that were
resistant to tamoxifen treatment. Their results showed that MKP-3 mRNA expression
was increased 2.5 times in resistant tumors compared to sensitive ones. They then used
an in vitro model of tamoxifen resistance. MCF7 and T47D cells were cultured long term
(over six months) in the presence of tamoxifen and used to confirm that MKP-3 mRNA
was increased in these cells compared to their tamoxifen sensitive counterparts. Using
MCF7 cells engineered to overexpress MKP-3, they next tested the effect of this
overexpression on tamoxifen sensitivity. They showed that MCF7 vector control cells
exhibited increased colony forming ability in the presence of estrogen and that this
increase was blocked following tamoxifen treatment.

MKP-3 overexpression cells

treated with estrogen exhibited a similar colony forming ability to vector control cells
treated with estrogen, but when these cells were treated with tamoxifen they showed a
ten-fold increase in colony formation compared to vector control cells under the same
conditions. Western blot analysis showed that MKP-3 overexpression cells treated with
tamoxifen had the highest level of activated ERK compared to vehicle or estrogen treated
MKP-3 overexpressing cells. To explain these seemingly paradoxical results, the authors
suggested that breast tumors might upregulate phosphatase expression to compensate for
chronic activation of ERK signaling.

They hypothesize that tamoxifen resistance
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emerges due to inactivation of MKP-3 phosphatase activity by ROS and that this loss of
activity disrupts the compensatory MAPK regulatory loop seen in breast tumors.48
In addition to tamoxifen resistance, MKP-3 has also been implicated in cisplatin
resistance in ovarian cancer. As mentioned previously, MKP-3 protein expression was
decreased in tumor tissue samples and ovarian cancer cell lines compared to normal
samples and immortalized, non-tumorigenic cell lines. Exogenous expression of MKP-3
in A2780cp cells, which are cisplatin resistant, increased their sensitivity to cisplatin
treatment up to 2.5-fold when compared to vector control cells.5,49
MKP-1 and Chemotherapy Resistance
Growing evidence suggests that MKP-1 may play a role in chemotherapy
resistance (Fig. 5).6 In human lung cancer cell lines, overexpression of MKP-1 protected
them from cisplatin-induced death.6,39 It was shown that MKP-1 targets JNK in response
to cisplatin, leading to increased c-Jun activity and that MKP-1-/- mouse embryo
fibroblasts (MEFs) were more sensitive to cisplatin and etoposide than MKP-1+/+ MEF
cells. This study also demonstrated that activation of JNK is required for sensitizing cells
to cisplatin.6,39 It has also been shown that induction of MKP-1 after treatment with
cisplatin is a general event in ovarian cancer cell lines, with knockdown of MKP-1 by
siRNA increasing cisplatin induced, JNK-mediated cell death.3,6
While MKP-1 has not yet been linked to tamoxifen resistance, it has been wellstudied in connection with resistance to many other chemotherapeutic agents in breast
cancer.

Overexpression of MKP-1 was able to protect breast cancer cells from

chemotherapy-mediated

apoptosis

when

they

were

treated

with

doxorubicin,

27

mechlorethamine and paclitaxel.6,57

This is significant because many chemotherapy

drugs, including anthracyclines, alkylating agents and taxanes, use JNK activation to
carry out their anticancer activity.4,6,57 A study in NSCLC looked at the effect of the
EGFR tyrosine kinase inhibitor AG1478 on JNK signaling. The results showed that
following treatment of PC-9 cells, MKP-1 expression was reduced.

Ectopic

overexpression of MKP-1 reduced JNK activation and decreased AG1478-induced
apoptosis.58 These results indicate that AG1478 also uses JNK activation as a mechanism
for apoptosis induction. Treatment of breast cancer cell lines with anthracyclines resulted
in the repression of MKP-1 and increased phosphorylation of ERK.59 Further silencing
of MKP-1 with siRNA resulted in decreased ERK activation, but the mechanism for this
remains unclear.6,59

A similar study looked at MKP-1 overexpression following

treatment with doxorubicin in a panel of breast cell lines.6,60

Results showed that

doxorubicin treatment decreased MKP-1 protein expression and that this decrease
preceded an increase in active ERK and JNK. MKP-1 staining was done in 30 complete
tissue sections that included histologic normal breast (n=30), as well as hyperplastic
(n=11), in situ (n=18) or infiltrating carcinomas (n=30) within the same tissue section.
MKP-1 was overexpressed in all in situ carcinomas and in 50% of infiltrating
carcinomas. This study also further characterized the effect of doxorubicin treatment ex
vivo in 50 patient samples, 27 of which did not show overexpression of MKP-1 and 23 of
which did. MKP-1 expression was decreased following doxorubicin in 39 samples, while
the other 11 samples showed a modest increase in MKP-1 levels. ERK and JNK

28

Figure 5. MKP-1 and chemoresistance. Overexpression of MKP-1 plays a role in the
development of resistance to chemotherapy in breast, lung and ovarian cancers. In breast
cancer, decreased JNK and p38 activity contributes to resistance to oxidative stress
induced death. Treatment with proteasome inhibitors increases ERK and decreases JNK
activity, leading to proteasome inhibitor resistance because of decreased levels of
apoptosis. Activation of the glucocorticoid receptor increases MKP-1 mRNA and leads
to decreased JNK and ERK activity, which factors in to paclitaxel resistance. Cisplatin
resistance in lung and ovarian cancer is caused in part by decreased JNK activity. (Figure
reproduced from Haagenson, K. K. & Wu, G. S. The role of MAP kinases and MAP
kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 29,
143-149, (2010).)
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activation increased following the downregulation of MKP-1, mirroring the results seen
in tumor cells. Additionally, in a series of 96 patients, it was shown that following
surgery and systemic treatment with chemotherapy, anti-hormonal therapy or both, those
who harbored MKP-1 overexpression were more likely to experience relapse than those
who did not, suggesting that MKP-1 might be a novel drug target in breast cancer.60
Proteasome inhibition has been linked to the induction of MKP-1 expression.6,61
This resulted in a decrease in ERK signaling and further blockade of ERK led to an
increase in proteasome inhibitor mediated apoptosis.6,61

This induction of MKP-1,

however, is thought to also limit the efficacy of proteasome inhibitors because of a
subsequent decrease in JNK activity, resulting in decreased levels of apoptosis.6,62
Knockdown of MKP-1 resulted in increased proteasome inhibitor sensitivity.6,62
Interestingly, evaluation of a combination treatment with proteasome inhibitors and
doxorubicin, which is known to decrease MKP-1 levels in breast cancer, showed
increased apoptosis, decreased MKP-1 levels and increased JNK phosphorylation in vitro
and resulting in delayed tumor growth in an in vivo xenograft model.6,62 Similar to the
combination of proteasome inhibitor treatment and doxorubicin, a combination of
proteasome inhibitor treatment and p38 blockade also inhibited MKP-1 expression,
increased JNK activity and increased apoptosis in the A1N4-myc and BT474 breast
cancer cell lines.6,63
Activation of the glucocorticoid receptor following treatment with dexamethasone
can also inhibit paclitaxel induced apoptosis by preventing the induction of ERK and
JNK activation.6,64 Activation of the glucocorticoid receptor has been shown to lead to
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an increase in MKP-1 mRNA, which could be an underlying mechanism for the decrease
in ERK and JNK activation. Using siRNA directed at MKP-1 decreased the antiapoptotic activity of glucocorticoids.6,64
Inhibition of JNK and p38 signaling by overexpression of MKP-1 also increased
resistance to H2O2-induced death in MCF7 breast cancer cells, with a correlation between
MKP-1 induction and the disappearance of phosphorylated MAPKs, suggesting that
MKP-1 might play a physiologic role in the inactivation of oxidative damage induced
MAPK activities. Furthermore, loss of MKP-1 sensitized cells to oxidative damage
induced death.4,6
Conclusion
These results show that, in general, overexpression of MKP-1 seems to contribute
to chemotherapy resistance in breast cancer, but MKP-1 involvement in tamoxifen
sensitivity has yet to be characterized.

Taking into consideration that MKP-1

phosphatase activity is preferentially directed toward JNK and p38 rather than ERK, this
suggests that increases in MKP-1 expression might contribute to changes in tamoxifen
sensitivity via the inhibition of JNK-mediated apoptosis.

MKP-2, which can

dephosphorylate all three MAPKs, but preferentially inactivates ERK and JNK, has also
been shown to be overexpressed in breast cancers. Both MKP-1 and MKP-2 proteins
have been shown to be stabilized following phosphorylation by ERK, forming a feedback
loop. The activation of the ERK pathway in tamoxifen resistant breast cancers is well
documented and has been connected to poor prognosis in patients. Taken together, these
data suggest that further investigation of the connection among MKPs, MAPK signaling
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and tamoxifen resistance is warranted, leading to the hypothesis that increases in MKP
expression are associated with changes in tamoxifen sensitivity. Investigating MKPs and
their regulation of MAP Kinases in breast cancer is important because tamoxifen
resistance is a major clinical problem and MAPK signaling has been implicated in its
development. In the research presented in this dissertation, the characterization of MKP1 and MKP-2 expression in breast cancer cells will form the knowledge base necessary to
begin to dissect their contributions to tamoxifen sensitivity. Investigating changes in
MAP Kinase activation and correlating them to MKP expression in both tamoxifen
sensitive and tamoxifen resistant cells will clarify the overall picture of MAPK signaling
in tamoxifen sensitivity and finally, examining the promoter sequence features of MKPs
will provide insight into their regulation in the context of breast cancer.
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CHAPTER 2
CHARACTERIZATION OF MKP-1 IN BREAST CANCER TAMOXIFEN
SENSITIVITY
Introduction
MKP-1 is the founding member of the MAP Kinase Phosphatase family. It has
the ability to dephosphorylate all three MAPKs, however at physiological levels seems to
preferentially inactivate JNK and p38.12 It is unclear what the precise physiological
function of MKP-1 is in normal tissues, as MKP-1 knockout mice show no obvious
phenotype.2 Other studies seem to indicate, however, that MKP-1 may be involved in the
inhibition of pro-inflammatory signaling.13

In vascular smooth muscle cells, MKP-1 is

activated by mechanical stress and seems to inhibit the proliferation of these cells through
MAPK dephosphorylation. MKP-1 has also been identified as a transcriptional target of
p53, suggesting it may play a role in cell cycle control.55 The second intron of MKP-1
contains a p53 binding site. This study also showed that when MKP-1 phosphatase
activity was inhibited using vanadate, a general phosphatase inhibitor, induction of p53mediated G1 arrest in response to growth factor stimuli was compromised. p53 also
regulates MKP-1 protein expression in response to oxidative stress in colon cancer
cells.56
Changes in MKP-1 expression in several cancer types have been shown to lead to
changes in metastatic potential and time to progression. In non-small cell lung cancer
(NSCLC), knockdown of MKP-1 by siRNA reduced the invasive ability and angiogenic
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potential of H460 cells and decreased tumorigenicity and metastasis in in vivo mouse
models.65 In colorectal cancer, MKP-1 expression in human tumor samples from patients
treated with cetuximab, a monoclonal antibody toward EGFR, was assessed in
conjunction with KRAS and BRAF mutational status. The results showed that patients
with wild-type KRAS and BRAF that overexpressed MKP-1 had a significantly shorter
time to progression than those that did not overexpress MKP-1.66
Particularly relevant to the studies presented here, MKP-1 has been shown to be
overexpressed in breast cancer24 and overexpression in other cancer types has been linked
to tumor progression, which suggests that inhibiting MKP-1 activity might be a strategy
to employ in the treatment of breast cancer. To this end, studies have been done to try to
identify small molecule inhibitors of MKP-1 from a pyrrole carboxamide library of
compounds.67,68 Structural analogs of the lead compound SID 3717140 were developed
in an attempt to identify MKP-1 inhibitors with improved potency, activity and
selectivity.67

A separate study using a pyrrole carboxamide library identified two

compounds, PSI2106 and MDF2085, which were determined to be potent and selective in
chemical screens, but their biological activity was not as good as expected.68 Subsequent
work in this area identified a cell active compound, NSC 95397, using a fluorescence
based chemical complementation assay.69

This compound was able to reverse

dexamethasone protection in paclitaxel treated cells. Combination treatment of NSC
95397 and paclitaxel in the absence of dexamethasone proved to be antagonistic, but in
the presence of dexamethasone, the effect of their combination was synergistic. These
results suggest that inhibition of MKP-1 occurred only in conditions of MKP-1
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upregulation.69 These data indicate that a considerable amount of effort is still needed to
discover small molecules capable of effectively inhibiting MKP-1. Success in this area
would be beneficial to dissecting the precise role of MKP-1 in the inhibition of
inflammatory signaling as well as its connection to tumor progression and chemotherapy
resistance.
In breast cancer, women who present with estrogen receptor positive disease are
treated with tamoxifen and it is well known that the development of recurrent, tamoxifen
resistant disease is a major problem in the clinical setting. MKP-1 has been connected to
chemotherapy resistance in lung, ovarian and breast cancers6. Thus far, no connection
has been made between MKP-1 and response to tamoxifen, but its history of being
involved in chemotherapy resistance suggests that the potential for a link between the two
be investigated further. In order to fully explore this possibility, this work will set out to
identify a cell line model appropriate to study the role of MKP-1 in tamoxifen sensitivity,
examine the response of MKP-1 protein expression following treatment with estrogen
and tamoxifen and determine if overexpression of MKP-1 contributes to changes in
tamoxifen sensitivity in breast cancer cells. These studies will form the foundation of
investigating the hypothesis that increases in MKP-1 expression are associated with
changes in tamoxifen sensitivity in breast cancer.
Materials and Methods
Cell Lines and Culture Conditions
MDA-MB-23170, T47D, CAOV3-pLKO.1 and CAOV3-shMKP1 cells were
cultured in Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10%
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fetal bovine serum (FBS). MCF10A cells were maintained in DMEM/F12 (1:1) medium
supplemented with 5% FBS, 10 µg/mL insulin, 20 ng/mL epidermal growth factor, 100
ng/mL cholera enterotoxin and 0.5 µg/mL hydrocortisone.71

MCF7 cells were

maintained in DMEM/F12 (1:1) medium supplemented with 5% FBS, 10 µg/mL insulin
and 0.5 nM estrogen.72

MCF7 tamoxifen resistant cells (MCF7-TAMR) cells were

generated in the lab of Dr. Malathy Shekhar by gradual exposure to increasing
concentrations of 4-OH-tamoxifen over a period of six months. (Gerard and Shekhar,
manuscript in preparation.) MCF7-TAMR cells are able to tolerate exposure of up to 10
µM TAM.

These cells were routinely maintained in DMEM/F12 (1:1) medium

supplemented with 5% FBS, 10 µg/mL insulin and 1 µM tamoxifen. MCF7 cells stably
expressing empty vector (pEGFP or pCDNA3.1) and MKP-14 or MKP-219 were
maintained in the same medium as MCF7 cells and stable clones were selected with 500
µg/mL G418. All cell lines were maintained in a 37°C incubator with a humidified
atmosphere consisting of 5% CO2. For experiments involving treatment with estrogen,
tamoxifen (TAM) or ICI 182,780 (ICI), cells were depleted of hormones by culturing in
phenol red free media supplemented with charcoal-stripped FBS and 10 µg/mL insulin.
Reagents
17-β-estradiol, G418 antibiotic and 4-OH tamoxifen were purchased from Sigma.
ICI 182,170 was purchased from Tocris. Human recombinant insulin was purchased
from GIBCO. Anisomycin (Sigma) was a gift from Dr. Raymond Mattingly.
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Whole Cell Lysates
To prepare whole cell lysates, cells were trypsinized with .05% Trypsin-EDTA
(GIBCO) and counted using a hemocytometer. 3 x 105 to 5 x 105 cells were plated in 60
mm dishes and allowed to adhere overnight. Treatments were added the following
morning. At the end of the treatment period, medium was removed and cells were
washed with ice cold phosphate-buffered saline (PBS). Following the removal of PBS,
cells were lysed with NP-40 lysis buffer (150mM NaCl, 1% NP40, 50 mM Tris-Cl)
containing a Complete Mini Protease Inhibitor Cocktail tablet (Roche Diagnostics). Cells
were detached by scraping and incubated on ice for one hour to ensure complete lysis,
then centrifuged at 14,000 rpm for ten minutes at 4°C to clear cell debris. Protein
concentration was determined using the Bio-Rad protein assay and absorbance was
measured at 595nm with a Genesys 10UV spectrophotometer (Spectronic Unicam). 2X
Laemmli’s sample buffer was added in equal volume to the lysates which were then
boiled for five minutes.
Western Blot Analysis
Steady state levels of protein expression were measured by western blot analysis.
Whole cell lysates were electrophoresed through a 12% polyacrylamide gel. Proteins
were transferred to a polyvinylidene diflouride membrane (Millipore) using a semi-dry
transfer method. Membranes were blocked for thirty minutes in either 10% milk (ECL
Plus detection), 5% bovine serum albumin (ECL Plus detection) or 0.1% casein in 0.2X
PBS (Odyssey detection) according to antibody specifications.

Membranes were

incubated in primary antibody overnight at 4°C, washed for ten minutes three times in
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either TBST (Tris-buffered saline with Tween 20; for detection with ECL Plus) or PBST
(Phosphate-buffered saline with Tween 20; for detection with Odyssey) and then
incubated with secondary antibody for one to two hours. Proteins were detected using
either the Amersham ECL Plus Western Blotting Detection Reagents Kit (GE
Healthcare) or the Odyssey Infrared imaging system according to the manufacturer’s
protocol.
Antibodies
MKP-1 (C-19) antibody and Estrogen Receptor  HC-20 antibody were
purchased from Santa Cruz Biotechnology. PhosphoPlus SAPK/JNK (Thr183/Tyr185)
Antibody Kit, PhosphoPlus p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) Antibody Kit,
Phospho-Estrogen Receptor  (Ser118) (16J4) antibody, GAPDH (D16H11) XP
monoclonal antibody, goat-anti-mouse-HRP and goat-anti-rabbit-HRP secondary
antibodies were purchased from Cell Signaling Technology.

Anti-V5 antibody was

purchased from Invitrogen. Anti--actin antibody was purchased from Sigma Aldrich.
When using the Odyssey scanner, Alexa-Fluor 680 conjugated to goat-anti-rabbit or goatanti-mouse (Invitrogen) or IRDye 800 conjugated to goat-anti-rabbit or goat-anti-mouse
(Li-Cor) were used as secondary antibodies.
RNA Isolation and cDNA Synthesis
1.0x106 cells were seeded in 10 cm dishes.

Cells were lysed using TRIzol

Reagent (Life Technologies) according to the manufacturer’s protocol to isolate total
RNA. RNA was quantified using the Genesys UV10 spectrophotometer (Spectronic
Unicam). Absorbance was measured at 260 and 280 nm and RNA concentration in µg/ul
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was calculated using the following formula: (OD260 x 100 x 40)/1000.

cDNA was

generated using the SuperScript III Reverse Transcriptase kit (Invitrogen) using 5 µg
total RNA as a template and random primers. All other steps were carried out according
to the manufacturer’s protocol. Samples were incubated in the PTC-200 Peltier thermal
cycler.
Real Time RT-PCR
Samples were tested in either duplicate or triplicate. Reactions were carried out
using the Choice-Taq DNA polymerase (Denville) in the PTC-200 Peltier thermal cycler
(MJ Research) under the following conditions: 95°C for 2 minutes, followed by thirtyfive cycles of 95°C for 15 seconds, 55°C for 30 seconds and 72°C for 60 seconds. The
final cycle was followed by a 5 minute extension step at 72°C. Primer sequences used
for both semi-quantitative and Real Time RT-PCR were as follows: GAPDH forward (5’ATC AAG AAG GTG GTG AAG CAG-3’, +946 to 966; NM_002046.4), GAPDH
reverse (5’-TGT CGC TGT TGA AGT CAG AGG-3’, +1042 to 1022; NM_002046.4),
MKP-1 forward (5’-GAA GTG GGC ACC CTG GAC GC-3’, +258 to 277;
NM_004417.3), MKP-1 reverse (5’-TGG CCG GCG TTG AAA GCG AA-3’, +364 to
345; NM_004417.3), MKP-2 forward (5’-GAG TCC GCG GTC CTC TCT CGT-3’,
+494 to 515; NM_001394.6) and MKP-2 reverse (5’-CCT CGC GGT CAC ATA GCA
GTC G-3’, +642 to 623; NM_001394.6).

Primers for MKP-1 and MKP-2 were

generated using the Primer BLAST software from NCBI. GAPDH primer sequences
were used previously in the lab of Dr. Michael Tainsky.73
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Real-Time PCR was carried out using the SYBR Green PCR core reagents kit
(Applied Biosystems). Each 20 µl reaction contained 2 mM MgCl2, 0.2 mM dNTPs, 0.1
mM forward and reverse primer mixture, 2 µl cDNA, 2 µl 10X SYBR Green, 0.5 U
AmpliTaq Gold Polymerase and sterile DNAse-RNAse free water (GIBCO). Samples
were run in 96 well plates using the Step One Plus Real-Time PCR System and Step One
Plus Software version 2.1 (Applied Biosystems).

Thermal cycling was conducted

according to the following protocol: 95°C for 10 minutes followed by forty cycles of
95°C for 15 seconds and 60°C for 60 seconds. Samples were then subjected to meltcurve analysis to make sure the products were free of primer dimers. Relative mRNA
quantitation was calculated using the Ct method with GAPDH used as the internal
control.
shRNA
CAOV3-pLKO.1 and CAOV3-shMKP-1 cells were generated in the Wu lab by
Dr. Juan Wang. Bacterial stocks of Mission shRNA (Sigma) directed against MKP-1 (5’CCGGCAAAGGAGGATACGAAGCGTTCTCGAGAACGCTTCGTATCCTCCTTTG
TTTTT-3’) were obtained and pLKO.1 vector DNA was stably transfected into CAOV3
ovarian cancer cells using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. Positive clones were obtained after selection with puromycin.
Four MKP-2 shRNAs subcloned into the pGIPZ vector (Open Biosystems) were
tested.

The MKP-2 targeting sequences were as follows: shRNA 1(RHS4430-

101067857): CCCCAGTGGAAGATAACCACAA; shRNA 2 (RHS4430-101069298):
ATTCGGTCAACGTGCGCTGTAA;

shRNA

3

(RHS4430-101073316):
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ACTGGTTCATGGAAGCCATAGA;
AGCCTACCTGATGATGAAGAAA.

shRNA

4

(RHS4430-98713911):

Constructs were transiently transfected into

MCF7-MKP-2 cells using Lipofectamine 2000 according to the manufacturer’s protocol.
Non-silencing shRNA was used as a negative control.
Sequence Alignment
Protein and DNA sequence alignments were performed with the ClustalW2
software program from the European Bioinformatics Institute. Default parameters were
used. Sequences were obtained from GenBank. The following accession numbers were
used: MKP-1 mRNA (NM_004417.3), MKP-1 protein (NP_004408.1), MKP-2 mRNA
(NM_001394.6) and MKP-2 protein (NP_001385.1).
Generation of MKP-1 and MKP-2 Overexpressing Cell Lines
Pooled populations of MCF7 cells overexpressing either MKP-1 [GenBank:
BC022463] or MKP-2 [GenBank: BC002671.2] and subcloned into the pCDNA3.1
expression vector were generated by stable transfection. Cells were transfected using the
Metafectine Easy transfection reagent (Biontex).

Briefly, 3 µl of metafectine was

incubated in 100 µl phenol red free, serum free DMEM/F12 (1:1) medium for twenty
minutes. Five micrograms of the empty pCDNA3.1 vector, pCDNA3.1-MKP-1 construct
or pCDNA3-MKP-2 construct DNA in 15 µl of DNAse-RNAse free water (GIBCO)
were added to the metafectine and incubated at room temperature for twenty minutes to
allow complexes to form. The mixture was added drop-wise to the cells. Stable clones
expressing V5-His tagged MKP-1 or MKP-2 were selected with G418 antibiotic (500
µg/mL) and pooled to minimize clonal bias. Stable pools of MCF7 cells expressing
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empty vector, MKP-1, or MKP-2 were maintained in DMEM/F12 (1:1) medium
supplemented with 5% FBS, 10 µg/mL insulin, 0.5 nM 17-β-estradiol and 500 µg/mL
G418.
MTT Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) assay
was used to measure cell viability following drug treatment. MCF7, MCF7-TAMR,
MCF7-pCDNA3.1-Pool, MCF7-MKP-1-Pool or MCF7-MKP-2-Pool (1x103 cells per
well) were seeded in triplicate in 96 well plates (day 0) and treated with vehicle (EtOH,
0.01% v/v), 10 nM E2, 100 nM TAM, 1000 nM TAM or a combination of 10 nM E2 and
1-, 10- or 100-fold molar excess TAM (day 1). Treatments were refreshed on day 4.
Assays were terminated on day 7 or when control wells reached 85% confluency,
whichever was longer. Cell viability was assessed by MTT assay (Sigma) and measured
on a Synergy 2 plate reader (BioTek) with Gen5 1.10 software.
Results
Before beginning to study the relationship between MKP-1 and tamoxifen
sensitivity, it was necessary to characterize its expression in breast cancer cell lines. In
order to select a cell line model to focus this study, a panel of breast cell lines was
screened for MKP-1 protein expression. This panel included the immortalized, nontumorigenic MCF10A cell line, the ER-negative MDA-MB-231 cells and ER-positive
MCF7 cells. MKP-1, a 39 kDa protein, was shown to be expressed in MDA-MB-231
cells (Fig 6A, Lane 2). MKP-1 protein was not detected in MCF10A or MCF7 cells. A 43
kDa band was shown to be highly expressed in MCF10A and MDA-MB-231 cells, but
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was only weakly detected in MCF7 cells (Fig. 6A). Similar results were seen in ERpositive T47D cells (data not shown). Real-time RT-PCR analysis showed that MCF10A
and MDA-MB-231 cells express similar levels of both MKP-1 and MKP-2 mRNA,
whereas MCF7 cells expressed low levels of both MKP-1 and MKP-2 mRNAs (Fig. 6B).
The undetectable level of MKP-1 protein in MCF7 cells, as well as the low expression of
the 43 kDa band, made it a good model to use for investigating the impact of MKP-1
overexpression.
Because the antibody used recognizes two bands, the ovarian cancer cell line
CAOV3, which is known to highly express MKP-1, was used to confirm which band
actually represents the protein. Compared to cells transfected with a non-target shRNA
(CAOV3-pLKO.1), cells transfected with MKP-1 shRNA (CAOV3-shMKP-1) showed a
decrease in expression in the 39 kDa band, confirming that the 39 kDa band is MKP-1
(Fig. 6C).
The antibody being using for these studies is a polyclonal MKP-1 antibody from
Santa Cruz. The antibody epitope is located within the last 50 amino acids of the MKP-1
C-terminus. The C-terminal region of MKP-1 contains the catalytic site, which is highly
conserved among MKP family members.13 MKP-2 is a 43 kDa protein and among the
MKP family members it is most similar to MKP-1 in that it is also a nuclear phosphatase
and is able to dephosphorylate all three MAPKs.11 To investigate whether the 43 kDa
protein could be MKP-2, the amino acid sequences of both MKP-1 and MKP-2 were
aligned using ClustalW2 software. This analysis showed that 29 of the 50 amino acids in
the MKP-1 antibody epitope are identical to those present in MKP-2 (Fig. 7).

To
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confirm further that the 43 kDa band observed in the previous study is indeed MKP-2,
four MKP-2 shRNA constructs from Open Biosystems were transiently transfected into
MCF7 cells engineered to overexpress MKP-2 with a V5-His tag (MCF7-MKP-2 cells)
and whole cell lysates prepared from these cells were analyzed by Western blot with
MKP-1 antibody (Fig. 8). It was found that shRNA constructs 3 and 4 greatly reduced
expression of both the 43 kDa band and the V5-His tagged band compared to the nontarget control. From this analysis it can be concluded that the 43 kDa band is MKP-2 and
that the MKP-1 antibody recognizes both MKP-1 and MKP-2 proteins.
Previous work in the field has demonstrated that MKP-1 expression can be altered
following drug treatment.58,60,61 After determining that MCF7 is an appropriate cell line
model, cells that were engineered to overexpress MKP-1 (MCF7-MKP-1 cells) were used
to investigate whether MKP-1 protein expression is altered following treatment with E2,
E2 plus 100-fold molar excess TAM or TAM alone (Fig. 9). Both the MCF7-MKP-1 and
MCF7-MKP-2 cells were derived from single clonal populations following positive
selection with G418 antibiotic. Cells were plated in phenol red free media and treated
with 1 or 10 nM E2, 100 nM or 1 µM TAM or the combination of E2 and TAM for 24 hr.
In both the vector control cells and MCF7-MKP-1 cells, no obvious change in MKP-1
protein expression was observed.
Interestingly, a small but noticeable increase in the expression of MKP-2 was
observed in both the vector control and MCF7-MKP-1 cell lines following tamoxifen
treatment when compared with the vehicle control (Fig. 9, Vector Control Lanes 5-7,
MCF7-MKP-1 Lanes 7-9). Since endogenous MKP-2 is increased by tamoxifen
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Figure 6. MKP-1 and MKP-2 protein and mRNA expression in breast cell lines. A.
Western blot showing the protein expression levels of MKP-1 (39 kDa) and MKP-2 (43
kDa) in a panel of breast cell lines. Whole cell lysates were probed with anti-MKP-1
antibody. Actin was used as a loading control. B. Real-Time RT-PCR analysis was used
to measure mRNA expression levels of MKP-1 and MKP-2 in the same panel of breast
cell lines. Relative mRNA levels were determined using the ΔΔCt method. GAPDH was
used as the internal control. Results are representative of at least three independent
experiments with each sample in triplicate. Error bars represent the standard error of the
mean. C. CAOV3 ovarian cancer cells were stably transfected with either a non-target
shRNA or shRNA toward MKP-1. Whole cell lysates were probed with anti-MKP-1
antibody. Actin was used as a loading control.
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Figure 7. MKP-1 and MKP-2 Amino Acid Sequence Alignment. The amino acid
sequences of MKP-1 and MKP-2 were aligned using the ClustalW2 software in order to
determine if the epitope of the MKP-1 antibody used in these studies could also recognize
MKP-2. Boxed area indicates the sequence containing the epitope of the MKP-1
antibody. Identical residues are shown in white.
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Figure 8. The 43 kDa protein recognized by the MKP-1 antibody is MKP-2. MCF7
cells engineered to overexpress MKP-2 with a V5-His tag were transiently transfected
with either a non-target control shRNA or one of four shRNA constructs targeting MKP2. Constructs 3 and 4 showed the ability to decrease MKP-2 and MKP-2-V5-His protein
expression. Whole cell lysates were probed with anti-MKP-1 antibody. Actin was used
as a loading control.
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Figure 9. MKP-1 protein expression is unchanged, but MKP-2 protein expression
increases following tamoxifen treatment. A. MCF7 vector control cells were treated
for 24 hrs. with either vehicle, 1 nM E2, 10 nM E2, 1 nM E2 and 100 nM TAM, 10 nM E2
and 1000 nM TAM, 100 nM TAM or 1000 nM TAM. Whole cell lysates were analyzed
by Western blot and membrane was probed with anti-MKP-1 antibody. Actin was used
as a loading control. B. MCF7-MKP-1 cells were treated as described in panel A.
Whole cell lysates were analyzed by Western blot and membrane was probed with antiMKP-1 antibody. Actin was used as a loading control. VC = MCF7 vector control cells.
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treatment, it suggests that MKP-2 expression may be regulated in an ER-mediated
manner. This possibility will be investigated in greater depth in subsequent chapters.
Next, it was necessary to investigate whether MKP-1 overexpression contributes
to changes in tamoxifen sensitivity. MTT assays were used to assess the effects of MKP1 overexpression on tamoxifen sensitivity. The assay was first conducted with parental
MCF7 cells, which are tamoxifen sensitive. These cells were plated in phenol red free
medium supplemented with charcoal stripped serum to minimize any baseline estrogenic
effects
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. On the following day, cells were treated with vehicle (EtOH, 0.01% v/v), 10

nM E2, 1000 nM TAM or a combination of 10 nM E2 and 100 or 1000 nM TAM.
Treatments were refreshed on Day 4 and the assay was allowed to continue for seven
days. Treatment with E2 showed approximately a 2.5 fold increase in cell proliferation
(p<0.01) and this increase was blocked by the addition of tamoxifen (Fig. 10A). These
results demonstrate that the MCF7 cells used in this study are indeed E2 responsive and
tamoxifen sensitive.
Before looking at the effect of MKP overexpression on TAM sensitivity, pooled
populations of MCF7 cells engineered to stably overexpress either MKP-1 or MKP-2
were generated to better reflect the heterogeneity known to be present in human tumors.
These cell lines express MKP-1 or MKP-2 with a V5-His tag. Western blot analysis was
conducted to confirm the presence of the V5 tag, which was expressed at the expected
size of MKP-1 at 43 kDa and MKP-2 at 48 kDa. The results of this analysis showed that
the V5 tag is present in the MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cells, but not in
MCF7-pCDNA3.1-Pool cells (Fig. 10B). MCF7-pCDNA3.1-Pool cells and MCF7-MKP-
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1-Pool cells were then subjected to MTT analysis (Fig. 10C). This assay was carried out
in regular medium because the cells were very sensitive to E2 withdrawal and showed
poor viability in phenol red-free medium.

Treatment with E2 doubled proliferation

(p<0.01) of MCF7-pCDNA3.1-Pool cells compared to vehicle control. Treatment with
TAM in the presence of E2 blocked this increase and cell proliferation was further
decreased with TAM alone. In the MCF7-MKP-1-Pool cells, overexpression of MKP-1
almost completely eliminated the E2-induced increase in cell proliferation. Treatment
with E2 plus TAM or TAM alone reduced cell proliferation by similar amounts compared
to vehicle control. The results of this assay suggest that overexpression of MKP-1 does
not increase the sensitivity of MCF7 cells to tamoxifen, but that it does decrease cell
proliferation in the presence of estrogen.
The decrease in cell proliferation in the presence of estrogen following MKP-1
overexpression suggests that the activity of MKP-1 is directed toward the MAPK that
drives the proliferation of these cells. To further investigate this, activation of two
MAPKs closely associated with cell growth, ERK1/2 and JNK1/2, was examined in
MCF7-pCDNA3.1-Pool and MCF7-MKP-1-Pool cells. Preliminary experiments failed to
detect p38 protein expression (data not shown), so it was not included in any further
experiments.

MCF7-pCDNA3.1-Pool and MCF7-MKP-1 Pool cells were plated in

phenol red-free medium and treated with either vehicle (EtOH, 0.01% v/v), E2, the
combination of E2 plus TAM, TAM alone, the combination of E2 and ICI 182,170 (ICI)
or ICI alone for four hours. This time point was chosen based on previous time course
experiments (data not shown). MCF7 cells that were serum-starved overnight and then
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treated with serum for 10 minutes were used as the positive control for ERK1/2
phosphorylation. Basal levels of phospho-ERK1/2 were observed in vector controls that
were not affected by treatment. This activity was completely eliminated following MKP1 overexpression (Fig. 11A). MCF7 cells treated with 10 ng/mL anisomycin for 30
minutes served as the positive control for JNK1/2 phosphorylation. JNK1/2 activation
was not detected in either cell line (Fig. 11B), suggesting that ERK1/2 signaling is a
major driver of MCF7 cell proliferation.
Conclusion
The MAP Kinase phosphatase MKP-1 has been linked to chemotherapy resistance
and is known to exhibit altered expression in many different cancer types, including
breast. This previous work led to the formulation of the hypothesis that an increase in
MKP-1 expression is associated with changes in breast cancer tamoxifen sensitivity. In
order to study this association, breast cell lines were screened for MKP expression. The
low expression of MKP-1 and MKP-2 in MCF7 cells made this cell line an ideal
candidate to study the effects of the overexpression of MKP-1 in breast cancer. The first
step was to examine the effect of E2 and TAM treatment on MKP-1 protein expression.
Treatment with E2, TAM or their combination revealed no obvious change in MKP-1
protein expression. E2 is known to increase cell proliferation by upregulating growth
factor pathways.22,35 TAM treatment blocks this activation. MKP-1 overexpression
failed to change tamoxifen sensitivity, exhibiting a similar cell viability profile to
tamoxifen-sensitive MCF7 vector control cells. MKP-1 overexpression did decrease cell
proliferation in the presence of E2 and examination of ERK1/2 and JNK1/2 activation in
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those cells showed that, compared to vector control cells, ERK1/2 phosphorylation was
completely eliminated and that JNK1/2 activation was not present in either cell line.
These data indicate that, contrary to the study hypothesis, MKP-1 does not play a role in
contributing to changes in breast cancer tamoxifen sensitivity. However, MKP-2 protein
expression was increased following tamoxifen treatment. This result suggests that MKP2 expression might be regulated via an ER mediated mechanism and that changes in
MKP-2 expression could play a role in contributing to changes in tamoxifen sensitivity.
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Figure 10. MKP-1 Overexpression Does Not Alter Tamoxifen Sensitivity. A. MCF7
cells were treated with Vehicle, E2, E2+TAM or TAM alone and subjected to MTT
analysis. Cells were treated on days 1 and 4. Absorbance was read on day 7. Results are
representative of at least three independent experiments with samples plated in triplicate.
Error bars represent the standard error of the mean. Statistical analysis was done using
Student’s t-test. ** = p<0.01 B. Western blot depicting the expression of the V5 tag in
MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cells. Population was selected with G418
antibiotic for one month and whole cell lysates were probed with V5 antibody. GAPDH
was used as a loading control. C. MCF7-pCDNA3.1-Pool and MCF7-MKP-1-Pool cells
were treated with Vehicle, E2, E2+TAM or TAM alone and subjected to MTT analysis.
Cells were treated on days 1 and 4. Absorbance was read on day 7. Results are
representative of at least three independent experiments with samples plated in triplicate.
Error bars represent the standard error of the mean. Statistical analysis was done using
Student’s t-test. ** = p <0.01
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Figure 11. MKP-1 Overexpression Eliminates ERK1/2 activation. A. MCF7pCDNA3.1-Pool cells and MCF7-MKP-1-Pool cells were treated with vehicle, E2, the
combination of E2+TAM, TAM alone, the combination of E2+ICI or ICI alone for four
hours. Serum-starved MCF7 cells were treated for 10 min. with serum and used as a
positive control for ERK1/2 phosphorylation. Whole cell lysates were analyzed by
western blot and membranes were probed with either phospho-ERK1/2 (P-ERK1/2) or
Total ERK1/2 antibody. GAPDH was used as a loading control. B. MCF7-pCDNA3.1Pool and MCF7-MKP-1-Pool cells were treated as described in panel A. MCF7 cells
treated with 10 ng/mL anisomycin for 30 minutes were used as a positive control for
JNK1/2 phosphorylation. Whole cell lysates were analyzed by western blot. Membranes
were probed with either phospho-JNK1/2 (P-JNK1/2) or Total JNK1/2 antibody.
GAPDH was used as a loading control.
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CHAPTER 3
CHARACTERIZATION OF MKP-2 IN BREAST CANCER TAMOXIFEN
SENSITIVITY
Introduction
The data presented thus far show that MKP-1 overexpression does not change
tamoxifen sensitivity of MCF7 cells, that MKP-1 protein expression is not obviously
altered after treatment with estrogen, tamoxifen or their combination and that MKP-2
protein expression increases under these conditions. These data suggest MKP-2, rather
than MKP-1, might be a player in tamoxifen sensitivity of MCF7 cells.
Next to MKP-1, MKP-2 is the best characterized MKP, although considerably
less is known about its role in cancer and chemotherapy resistance. MKP-2 was first
identified by Misra-Press et al in 1994.54 The authors of this study demonstrated that
MKP-2 is expressed in a wide variety of rat tissues in a profile that is overlapping yet
distinct from MKP-1. They also suggested that this differential expression combined
with the unique N-terminal sequences of the two phosphatases indicate distinct functional
roles for each protein.54
Subsequent work by this group investigated the ability of MKP-1 and MKP-2 to
dephosphorylate the stress-activated MAPK, JNK.75 Their analysis revealed that MKP-1
was better able to dephosphorylate JNK-1 than MKP-2 and that both phosphatases
showed similar abilities to dephosphorylate JNK-2.75

Further analysis of MKP-2

substrate specificity showed that it is also able to dephosphorylate ERK1/2, but had little
effect on p38.11 These analyses of substrate specificity were conducted using
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exogenously expressed proteins. Additionally, MKP-2 substrate specificity has not been
examined in the context of tamoxifen sensitivity. Recently, MKP-2 knockout mice were
created to study MKP-2 physiological function. This study showed that deletion of
MKP-2 decreased cell proliferation and cell cycle analysis showed that MKP-2-/- MEFS
accumulated in the G2/M phase, suggesting that MKP-2 might play a role in cell cycle
progression.76
Studying the transcriptional regulation of MKP-2 has provided insight into its
possible mechanistic role in cancer.

Evidence has been put forth that MKP-2 is a

transcriptional target of p53 in response to oxidative stress. This would seem to be
consistent with the idea that MKP-2 might play a role in cell cycle regulation.77 The
authors of this study suggested that MKP-2 might contribute to tumor suppression77,
which is certainly contrary to the notion that it would play a role in cell cycle
progression. MKP-2 has also been identified as a transcriptional target of E2F-1. E2F-1-/MEFs showed decreased levels of H2O2-induced MKP-2 protein compared to E2F-1+/+
MEFs and also displayed resistance to oxidative stress induced cell death78. When MKP2 was overexpressed in MCF7 cells, these cells were more sensitive to H2O2 treatment
than vector control cells. MCF7 cells overexpressing MKP-2 also showed decreased
colony formation in soft agar compared to vector control.78 When injected into female
athymic nude mice, MCF7-MKP-2 cells formed tumors in 2 of 12 mice, whereas all mice
injected with vector control cells formed tumors.78
The exploration of the expression of MKP-2 in cancer has been limited thus far.
As discussed in Chapter 1, its expression levels have been examined in pancreatic44,
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liver43, ovarian9 and breast cancers24, as well as in glioblastomas45. MKP-2 expression
has been shown to be upregulated in all of these cancer types, with the exception of
ovarian cancer and glioblastoma. In primary tumors as well as in glioblastoma cell lines,
methylation of a CpG island in the MKP-2 promoter was detected.45 MKP-2 promoter
methylation was found to occur more frequently in tumors with p53 mutation, but in
tumors with amplified EGFR it was virtually absent. Additionally, the overexpression of
MKP-2 in glioma cell lines showed a decrease in cell proliferation, furthering the idea
that MKP-2 plays a role in growth suppression.45 Another study that supports this idea
showed that the MKP-2 promoter was more highly methylated in basal-like breast tumors
resected following neo-adjuvant chemotherapy compared to other breast cancer subtypes
and overexpression of MKP-2 in these tumors increased chemotherapy-induced
apoptosis.79 These results suggest that loss of MKP-2 expression may contribute to
chemotherapy resistance.
Prior to the work presented in this chapter, no connections had been made
between MKP-2 expression and the role it plays in regard to tamoxifen sensitivity. To
investigate this, MKP-2 gene and protein expression were characterized in tamoxifen
sensitive and tamoxifen resistant cells, along with the effect of MKP-2 overexpression on
cell proliferation following tamoxifen treatment. The putative promoter of MKP-2 has
also been identified in order to study the regulation of MKP-2 gene expression in
response to estrogen and tamoxifen treatments. The studies presented here collectively
show that MKP-2 is expressed in tamoxifen resistant cells, that overexpression of MKP2 decreases cell proliferation in response to estrogen yet maintains tamoxifen sensitivity,
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and that MKP-2 promoter activity is not changed following E2 or TAM treatment. These
data suggest that in the context of tamoxifen resistance, MKP-2 may be upregulated to
return the cell to a tamoxifen sensitive phenotype.
Materials and Methods
Cell culture, generation of whole cell lysates, Western blot analyses, MTT assays,
RNA isolation and real-time RT-PCR were conducted as described in the Materials and
Methods section of Chapter 2.
Identification of the Putative MKP-2 Promoter
The putative promoter of MKP-2 was identified using the Genomatix software
suite by entering DUSP4 in the Gene2Promoter database and aligning the resulting
sequences with the gene sequence of MKP-2 (gene id 1846). The promoter sequence that
was determined to be the best match was GXP_35747, a 1207 bp sequence on the
negative strand of chromosome 8 from bp 29,208,769 to 29,207,563. Transcription
factor binding sites were identified using the MatInspector program.
Amplification of the MKP-2 Promoter
The promoter of MKP-2 was amplified from human placental genomic DNA
using primers containing XhoI (forward primer) and HindIII (reverse primer) restriction
sites to facilitate the cloning of the promoter into the appropriate vectors. The primer
sequences were as follows: MKP-2-pro-XhoI (5’-CCG CTC GAG GGC TGT CAC GCG
GGG AAG CG-3’; +1 to 20; Genomatix accession id: GXP_35747) and MKP-2-proHindIII (5’-CCC AAG CTT TTA GCC CGC CGC CGC ACG AT-3’; +1207 to 1188;
Genomatix accession id: GXP_35747).

The MKP-2 promoter was amplified using
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Choice Taq DNA polymerase (Denville) in a PTC-200 Peltier thermal cycler under the
following conditions: 95°C for 5 min, followed by 35 cycles of a 1 min, 95°C denaturing
step, 2 min, 55°C annealing step and 3 min, 72°C extension step. Upon the completion
of 35 cycles, a 10 minute final extension step was performed at 72°C.
Cloning of the MKP-2 Promoter
The putative MKP-2 promoter was cloned into the pCR-TOPO4 TA cloning
vector (Invitrogen). The fragment containing the putative MKP-2 promoter was released
from the TA cloning vector using the EcoRI (Invitrogen) restriction sites according to the
manufacturer’s protocol. The promoter fragment was subsequently digested with XhoI
and HindIII and subcloned into the pGL3-Basic Luciferase Reporter vector (Promega)
using the XhoI and HindIII (New England Biolabs) restriction sites according to the
manufacturer’s protocol.
Sequencing
Sequencing of the pCR4-MKP-2 promoter construct was carried out by Genewiz
using the M13 forward (5’-ACT GGC CGT CGT TTT AC-3’) and reverse (5’-ACA
GGA AAC AGC TAT GA-3’) priming sites found on the pCR4-TOPO vector. After
subcloning the MKP-2 promoter into the pGL3-Basic vector, the construct was
sequenced by Genewiz using the MKP-2-pro-XhoI (forward) and MKP-2-pro-HindIII
(reverse) primers (see Cloning section above for sequences) as well as the GLprimer2
primer (5’-TGG AAG ACG CCA AAA ACA TAA AG-3’), which recognizes the
luciferase transcription start site present in the pGL3-Basic vector.
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Transfection and Luciferase Reporter Assay
Transfection of the empty pGL3 and pGL3-MKP-2-pro constructs into MCF7,
MCF7-TAMR and MDA-MB-231 cells (2.5 x 105 cells per well in 6 well plates) was
carried out using the Metafectine Easy transfection reagent (Biontex). Briefly, 5 µl of
metafectine was incubated in 100 µl phenol red free, serum free DMEM/F12 (1:1)
medium for twenty minutes. Five micrograms of either empty pGL3 or pGL3-MKP-2pro DNA and 0.5 ng of pRLTK (expressing Renilla luciferase and serving as an internal
control) in 15 µl of DNAse-RNAse free water (GIBCO) was added to the metafectine
and incubated at room temperature for twenty minutes to allow complexes to form. The
mixture was added drop-wise to the cells.

Vehicle, E2, TAM or ICI treatments were

added 24 hrs post-transfection. Luciferase reporter activity was measured 48 hrs posttransfection using the Dual Luciferase Reporter Assay System (Promega) according to
the manufacturer’s protocol. The TD-20/20 luminometer (Turner Designs) was used to
read the luciferase activity of each sample.
Results
The data presented thus far show that overexpression of MKP-1 does not change
tamoxifen sensitivity in MCF7 cells and that MKP-2 protein was increased with
tamoxifen treatment. It was important to verify a potential role for MKP-2 in tamoxifen
sensitivity under physiological conditions. This was done with an isogenic model of
acquired tamoxifen resistance (MCF7 and MCF7-TAMR cells). MCF7 cells that had
been selected with increasing amounts of tamoxifen for over six months (MCF7-TAMR
cells) were obtained from the lab of Dr. Malathy Shekhar. MKP protein expression in
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these cells was determined by western blot analysis and it was shown that as compared to
parental MCF7 cells, MKP-2 protein expression was 3.5–fold higher and that MKP-1
protein expression was not detectable (Fig. 12A). This was supported by real-time PCR
analysis, which showed that MKP-2 mRNA was increased 12-fold in tamoxifen resistant
cells when compared to parental MCF7 cells and that MKP-1 mRNA expression was
negligible (Figure 12B).
To further characterize the MCF7-TAMR cells, MTT analysis was carried out in
phenol red free medium as described previously. It was found that these cells showed a
modest increase in proliferation when treated with 10 nM E2 and that tamoxifen treatment
did not block this increase, but in fact further stimulated cell proliferation. This indicates
that these cells are not sensitive to estrogen and are indeed tamoxifen resistant (Fig 12C).
Since it has been shown that phosphorylation of Ser118 in the estrogen receptor leads to
its ligand-independent activation and it has been suggested that this site is associated with
tamoxifen resistance, phosphorylation of this site in MCF7 and MCF7-TAMR cells was
examined (Fig. 13). Cells were plated in phenol red-free medium and treated with
vehicle (EtOH, 0.01% v/v), 10 nM E2, 1 µM tamoxifen, the combination of E2 and 100fold molar excess tamoxifen, the combination of 10 nM E2 and 100-fold molar excess ICI
or 1 µM ICI for 4 hours.
phosphorylation.

In both cell lines, estrogen treatment increased Ser118

This increase was reduced by treatment with anti-estrogens.

Additionally, MKP-2 protein expression in MCF7 (Fig. 13A) and MCF7-TAMR (Fig.
13B) cells under these conditions was examined. In MCF7 cells, MKP-2 levels were
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Figure 12. Characterization of MCF7-TAMR Cells. A. MKP-2 protein expression is
increased in MCF7-TAMR cells compared to MCF7 parental cells. Whole cell lysates
were analyzed by western blot and probed with anti-MKP-1 antibody. MCF7-MKP-1
cells were included as a positive control for MKP-1 expression. B. MKP-2 mRNA
expression is increased in MCF7-TAMR cells compared to MCF7 parental cells. Gene
expression was detected by qRT-PCR. GAPDH was used as an internal control. Results
are representative of two independent experiments. Samples were plated in triplicate.
Error bars represent the standard error of the mean. C. MCF7 and MCF7-TAMR cells
were treated with vehicle, E2, E2+TAM or TAM alone and subjected to MTT analysis.
Cells were treated on days 1 and 4. Absorbance was read on day 7. Results are
representative of at least three independent experiments with samples plated in triplicate.
Statistical analysis was done with Student’s t-test. ** = p<0.01
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Figure 13. MKP-2 protein expression is increased following anti-estrogen treatment
in MCF7 cells and constitutively expressed in MCF7-TAMR cells. A. MCF7 cells
were treated with vehicle, E2, E2+TAM, TAM alone, E2+ICI or ICI alone for 4 hours in
phenol red free medium. Whole cell lysates were subjected to western blot analysis and
probed with antibody toward P-S118, total ERα, or MKP-2. Actin was used as a loading
control. B. MCF7-TAMR cells were treated with vehicle, E2, E2+TAM, TAM alone,
E2+ICI or ICI alone for 4 hrs in phenol red free medium. Whole cell lysates were
subjected to western blot analysis and probed with antibody toward P-S118, total ERα or
MKP-2. Actin was used as a loading control.
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slightly increased with anti-estrogen treatment, which is similar to what was observed in
vector control and MKP-1 overexpression cells previously (Fig. 9). In MCF7-TAMR
cells, however, MKP-2 was shown to be constitutively expressed, regardless of treatment
condition. MKP-1 expression was not detected in either cell line.
To study MAP Kinase activation in these cells, levels of phosphorylated ERK1/2
in both MCF7 and MCF7-TAMR cells following 4 hour treatment with 10 nM E2, 1 µM
tamoxifen, 1 µM ICI or the combination of estrogen and tamoxifen or estrogen and ICI
were examined (Fig. 14).

MCF7 cells that were serum-starved overnight and

subsequently treated with serum for 10 minutes served as a positive control for ERK1/2
phosphorylation. Following treatment with E2, basal ERK1/2 phosphorylation in MCF7
cells was observed at a similar level as vehicle control and this phosphorylation was
decreased following treatment with E2 plus TAM, TAM alone, E2 plus ICI and ICI alone,
suggesting that levels of phosphorylated ERK1/2 in MCF7 cells are responsive to antiestrogen treatment (Fig. 14A). Previous work in the field has shown that treatment of
MCF7 cells with E2 induces ERK1/2 phosphorylation to a much greater extent than
shown here.80 This is possibly due to the absence of phosphatase inhibitors in the lysis
buffer used to generate whole cell lysates. In MCF7-TAMR cells, ERK1/2 activation
was present regardless of treatment condition (Fig. 14B). JNK1/2 activation was also
examined in both cell lines, with MCF7 cells treated with anisomycin for 30 minutes
serving as a positive control. JNK1/2 phosphorylation could not be detected in either
MCF7 (Fig. 14A) or MCF7-TAMR cells (Fig. 14B).
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As mentioned in Chapter 2, in order to study the role of MKP-2 in tamoxifen
sensitivity, a pooled population of MCF7 cells engineered to overexpress MKP-2 was
generated. MKP-2 protein expression was measured in the MCF7-pCDNA3.1-Pool cells
and the MCF7-MKP-2-Pool cells (Fig. 15A). MKP-2 expression was low in MCF7pCDNA3.1-Pool cells. In the MCF7-MKP-2-Pool cells, endogenous MKP-2 expression
was present at low levels, while exogenous MKP-2 expression was present at higher
levels. These cells were then used to perform an MTT assay under the same treatment
conditions described previously (Fig. 15B).

The vector control cells used in this

experiment were the same as those used in Fig. 10. MCF7-MKP-2-Pool cells showed a
decreased response to estrogen, but maintained tamoxifen sensitivity. These data suggest
that MKP-2 overexpression inhibits cell proliferation in response to estrogen, but retains
sensitivity to tamoxifen.
As noted earlier, in MCF7-TAMR cells, MKP-2 protein expression is increased
compared to MCF7 cells and is constitutively expressed regardless of treatment
condition. To further assess the role of MKP-2 activity in the context of tamoxifen
response, MCF7-pCDNA3.1-Pool, MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cells
were treated with vehicle, E2 or the combination of E2 and one of three increasing
concentrations of TAM and cell proliferation was analyzed using an MTT assay (Fig.
15C).

Compared to the vector control cells, overexpression of MKP-2 caused a

significant (p<0.05) decrease in cell proliferation following E2 treatment. Treatment with
a combination of E2 with 1, 10 or 100-fold molar excess TAM resulted in dose-dependent
inhibition of MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cell proliferation.
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Figure 14. Phosphorylation of ERK1/2 in MCF7 cells is responsive to anti-hormone
treatment. A. MCF7 cells were treated with vehicle, E2, E2+TAM, TAM alone, E2+ICI
or ICI alone for 4 hours in phenol red free medium. Serum starved MCF7 cells were
treated with serum for 10 minutes and were included as a positive control for ERK1/2
phosphorylation. MCF7 cells treated with 10 ng/mL anisomycin for 30 minutes were
included as a positive control for JNK1/2 phosphorylation. Whole cell lysates were
subjected to western blot analysis and probed with antibody toward P-ERK1/2, total
ERK1/2, P-JNK1/2 or total JNK1/2. GAPDH was used as a loading control. B. MCF7TAMR cells were treated as described in Panel A.
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Figure 15. Overexpression of MKP-2 affects cell proliferation in response to E2, and
increases TAM sensitivity compared to vector control and MKP-1 overexpressing
cells. A. Whole cell lysates of MCF7-pCDNA3.1-Pool and MCF7-MKP-2-Pool were
treated with vehicle, E2, E2+TAM, TAM, E2+ICI or ICI for 4 hours, then subjected to
western blot analysis and probed with antibody toward MKP-1. GAPDH was used as a
loading control. B. MCF7-pCDNA3.1-Pool cells and MCF7-MKP-2-Pool cells were
treated with vehicle, 10 nM E2, E2+TAM, 100 nM TAM or 1000 nM TAM and MTT
analysis was performed. Cells were treated on days 1 and 4. Absorbance was read on
day 7. Results are representative of at least three independent experiments with samples
plated in triplicate. Statistical analysis was done using Student’s t-test. ** = p<0.01 C.
MCF7-pCDNA3.1-Pool cells, MCF7-MKP-1-Pool cells and MCF7-MKP-2-Pool cells
were treated with vehicle, E2 or E2 plus one of three increasing concentrations of TAM
and and MTT assay was performed. Cells were treated on days 1 and 4 and absorbance
was read on day 7. Results are representative of two independent experiments with
samples plated in triplicate. Statistical analysis was done using Student’s t-test. * =
p<0.05, ** = p <0.01, *** = p<0.001
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Compared to vector control or MKP-1 overexpressing cells, MKP-2 overexpressing cells
were associated with greater tamoxifen sensitivity as significant (p<0.01) decreases were
observed at all three doses of tamoxifen.
To identify the MAPK that MKP-2 was inactivating, ERK1/2 and JNK1/2
phosphorylation were measured by western blot (Fig. 16). The vector control cells
shown here are the same as those in Fig. 11. As discussed before, basal ERK1/2
activation was observed and JNK1/2 activation was not present in these cells (Fig. 16A).
MKP-2 overexpression completely abolished ERK1/2 activity. As expected, no JNK1/2
phosphorylation was detected (Fig. 16B), suggesting that ERK1/2 is a major driver of
proliferation in these cells.
The increase in MKP-2 protein expression following treatment with tamoxifen
suggested that the MKP-2 promoter might be regulated via an ER-mediated mechanism.
In order to investigate this, the Genomatix software suite was used to identify the putative
promoter for MKP-2, and MatInspector was used to locate putative transcription factor
binding sites. This analysis revealed that there are three estrogen response element
(ERE) half sites within the putative promoter sequence, two on the negative strand, which
is the DNA strand containing the MKP-2 gene, and one on the positive strand. Fig. 17
shows the MKP-2 gene with the promoter region, and the putative ERE half sites.
Although these are not canonical EREs in the sense that a full response element is not
present, the presence of a single ERE half site has been shown to be sufficient to
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Figure 16. Overexpression of MKP-2 eliminates ERK1/2 phosphorylation. A.
MCF7-pCDNA3.1-Pool and MCF7-MKP-2-Pool cells were plated in phenol red-free
medium and treated with vehicle, E2, E2+TAM, TAM, E2+ICI or ICI for 4 hours. Whole
cell lysates were analyzed by western blot and probed with either P-ERK1/2 or total
ERK1/2 antibody. Serum starved MCF7 cells treated with serum for 10 minutes were
used as positive control for ERK1/2 phosphorylation. GAPDH was used as a loading
control. B. MCF7-pCDNA3.1-Pool and MCF7-MKP-2-Pool cells were treated as
described in Panel A. Whole cell lysates were analyzed by western blot and probed with
either P-JNK1/2 or total JNK1/2 antibody. MCF7 cells treated with 10 ng/mL
anisomycin for 30 minutes were included as a positive control for JNK1/2
phosphorylation. GAPDH was used as a loading control.
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produce a response to estrogen if stabilized through interactions with another
transcription factor.30 Interestingly, these ERE half sites in the putative MKP-2 promoter
are located in very close proximity to canonical AP-2 response elements.
To study MKP-2 promoter regulation, the MKP-2 promoter was amplified from
human placental genomic DNA. The promoter fragment was subcloned into the pCR4TOPO TA cloning vector. After obtaining a clone positive for the MKP-2 promoter, it
was verified by sequencing using M13 primers that recognize the pCR4 vector sequence.
Sequence analysis confirmed that the insert was the MKP-2 promoter and that no
mutations had been introduced during the amplification and cloning process. The next
step was to subclone the promoter into the pGL3-Basic vector. This was done using the
XhoI and HindIII restriction sites. Restriction digest analysis was performed with the
XhoI and HindIII enzymes and showed that the insert was the same size obtained from
the TA cloning vector (Fig. 18). The presence of the MKP-2 promoter was verified by
sequencing with the primers initially used to isolate it, as well as a primer that recognized
the transcription start site of the luciferase reporter gene present in the pGL3-Basic
vector. The results of both of these sequencing reactions confirmed the presence of the
MKP-2 promoter and that no mutations were introduced during cloning.
Once the MKP-2 promoter-driven luciferase reporter construct was created, its
activity was tested in MDA-MB-231 cells, as MDA-MB-231 cells express high levels of
MKP-2 mRNA (Fig. 6), indicative of elevated MKP-2 promoter activity. The cells were
transfected with either the empty pGL3, or 2, 3, 5 or 10 µg of the pGL3-MKP-2-pro
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Figure 17. The putative MKP-2 promoter contains ERE half sites. Schematic
depicting the sequence features of the MKP-2 promoter, including estrogen response
element half sites and AP-2 transcription factor binding sites.
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Figure 18. The putative MKP-2 promoter is subcloned into the pGL3-Basic
Luciferase Reporter vector. Following TA cloning and subcloning into pGL3-Basic
vector, constructs underwent restriction digest analysis with XhoI and HindIII to confirm
presence of MKP-2 promoter insert. Products were run on a 1% agarose gel.
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construct with Renilla luciferase used as an internal control. MKP-2 promoter-driven
luciferase was expressed robustly in MDA-MB-231 cells and increased with increasing
amounts of MKP-2 promoter DNA transfection (Fig. 19A). These data suggest that the
putative MKP-2 promoter sequence possesses promoter activity. Next, the pGL3-MKP2-pro construct was transfected into MCF7 and MCF7-TAMR cells. Cells were plated in
phenol red free medium and transfected with 5 µg of either the pGL3-Basic vector or the
pGL3-MKP-2-pro construct along with pRLTK. On the day following transfection, cells
were treated with vehicle (EtOH, 0.01% v/v), 10 nM E2, 1 µM TAM, 1 µM ICI or the
combination of E2 plus TAM or E2 plus ICI. Levels of basal reporter gene activation in
MCF7 and MCF7-TAMR cells were substantially lower than in the ER-negative MDAMB-231 cells, and treatment with E2, TAM or ICI did not alter the basal activity in MCF7 and MCF-7-TAMR cells.

Since promoter activity was seen in MDA-MB-231 cells,

this suggests the presence of functional transcription regulatory elements in the 1207 bp
fragment used for MKP-2 promoter analysis. The weak activity exhibited in MCF7 and
MCF7-TAMR cells may be due to low transfection efficiency, as Renilla luciferase levels
were much lower in MCF7 and MCF7-TAMR cells as compared to MDA-MB-231 cells.
Since the basal activities of the promoter construct were unaffected by hormones, it is
possible that the hormonal response elements capable of regulating MKP-2 promoter
activity reside outside the selected DNA fragment, or that MKP-2 gene expression is not
controlled by classical ER regulated mechanisms. However, since MCF7-TAMR cells
express higher levels of MKP-2 mRNA compared to parental MCF7 cells, this suggests
that a more detailed analysis of MKP-2 promoter regulation is warranted. Another
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Figure 19. MKP-2 promoter driven luciferase activity. A. Increasing amounts of the
pGL3-MKP-2-pro construct were transfected into MDA-MB-231 cells to test construct
activity. 4.0 x 105 cells were plated in 6-well plates and luciferase activity was measured
48 hr. post-transfection. B. The pGL3-MKP-2-pro construct was transfected into MCF7
cells to examine regulation of MKP-2 promoter following treatment with vehicle, 10 nM
E2, 10 nM E2+1µM TAM, 1µM TAM, 10 nM E2+1µM ICI or 1 µM ICI. 2.5 x 105 cells
were plated in phenol red-free medium in 6-well plates. Treatments were administered
24 hrs post-transfection and luciferase activity was measured 48 hr. post-transfection.
Results represent the average of three independent experiments. Error bars represent the
standard error of the mean. C. MCF7-TAMR cells were transfected with the pGL3MKP-2-pro construct and luciferase activity was measured as described in Panel B.
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possible explanation for the observed accumulation of MKP-2 protein in MCF7-TAMR
cells is its post-translational modification by ERK1/2 or another kinase.

As noted

previously, MKP-2 protein can be phosphorylated by active ERK1/2, which stabilizes the
protein.19 This phosphorylation is required to prevent rapid proteasomal degradation and
to allow MKP-2 to carry out the dephosphorylation of MAPKs.19 Taking these results
together, it is clear that further investigation is necessary to identify the mechanisms
responsible for regulating MKP-2 in response to tamoxifen treatment.
Conclusion
MKP-2, a nuclear MKP that preferentially activates ERK and JNK1/2 over
p38,11,75 has been shown to be overexpressed in breast cancer tissues24, but no connection
had been made previously between MKP-2 expression and its role in tamoxifen
sensitivity. The data presented here have shown that compared to parental MCF7 cells,
MCF7-TAMR cells exhibit increased MKP-2 gene and protein expression and that MKP1 gene and protein expression are negligible.

MTT analysis revealed that MKP-2

overexpression diminishes cell proliferation in response to estrogen compared to vector
control cells, but that tamoxifen sensitivity was maintained. MKP-2 expression was
increased following tamoxifen treatment and a 1207 bp putative promoter was identified.
Its regulation by E2 and anti-estrogens was examined in MCF7 and MCF7-TAMR cells.
MKP-2 basal promoter activity was low and treatment with hormone had no influence on
basal activity. However, this 1207 bp fragment showed robust luciferase reporter activity
in MDA-MB-231 cells. These data suggest that elements regulating hormonal response
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of MKP-2 probably lie outside the 1207 bp fragment used for the promoter assay or that
MKP-2 gene expression is controlled by non-classical E2 responsive mechanisms.
Taken together, the results presented in this chapter suggest that MKP-2
overexpression sensitizes breast cancer cells to tamoxifen treatment and that tamoxifen
resistant cells upregulate MKP-2 expression to potentially return them to a tamoxifen
sensitive state. In a proposed working model (Fig. 20), treatment of MCF7 cells with
tamoxifen increases MKP-2, which dephosphorylates ERK1/2.

MCF7 cells are

dependent on E2/ERα for activation of ERK1/2, which is inhibited by tamoxifen.
Dephosphorylation of ERK1/2 by tamoxifen-induced MKP-2 slows cell proliferation and
induces cell death. In tamoxifen resistant MCF7 cells, phosphorylated ERK1/2 is present
at high levels. These cells are insensitive to E2 and ERK1/2 activation is driven by
growth factor signaling pathways, such as EGFR and HER2, which are known to be
overexpressed in tamoxifen resistant tumors.36 MKP-2 levels are upregulated in TAMR
cells, but are unable to inhibit ERK1/2 activation probably because of robust activation of
ERK1/2 by growth factor pathways. Previous work in our lab has shown that activated
ERK1/2 phosphorylates MKP-2 on Ser 386 and Ser 391, which stabilizes the MKP-2
protein and protects it against proteasomal degradation without affecting its catalytic
activity.19

76

In
tamoxifen sensitive cells, phosphorylated ERK1/2 is present, indicating that cell-growth
signaling pathways are activated. Following treatment with anti-estrogens such as TAM,
MKP-2 protein expression is increased, which leads to the dephosphorylation of active
ERK1/2, slowing or eliminating cell proliferation. In tamoxifen resistant cells,
phosphorylated ERK1/2 is constitutively present at higher levels than in tamoxifen
sensitive cells. These cells are constantly upregulating MKP-2 protein expression in an
attempt to return the level of active ERK1/2 to that of a tamoxifen sensitive cell.
Continuous stimulation of ERK1/2 by growth factors, which are not sensitive to
inhibition by tamoxifen, leads to the persistence of growth signals in the cell.
Figure 20.

Working model depicting the role of MKP-2 in tamoxifen sensitivity.
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CHAPTER 4
SUMMARY AND DISCUSSION OF CONCLUSIONS
It is no secret that the emergence of resistance to currently available therapies is a
major problem seen all too frequently in the clinical setting.

Research aimed at

discovering the mechanisms underlying drug resistance and finding biomarkers that
would be able to classify tumors as either drug resistant or drug sensitive has been a
major focus of the field in recent years. Cell signaling pathways have been central
figures in many of these studies.

One such family of signaling pathways that has

emerged as a player in breast cancer progression and resistance is the MAP Kinase
family.
In mammalian cells, the MAPK family is made up of three branches: ERK, JNK
and the p38 MAPKs.

These kinases are activated by a variety of cellular stimuli,

including growth factors, cytokines and cellular stress.2-6 ERK1/2 in particular has been
shown to have increased activity in breast tumors and to be connected to poor prognosis
and endocrine therapy resistance in breast cancer patients.23,32

Subsequent research

revealed that it was possible to pharmacologically inhibit ERK1/2 activity and restore
TAM sensitivity.38 This begs the question: what role do MAP Kinase Phosphatases, the
endogenous negative regulators of MAPKs, have in affecting the tamoxifen sensitivity of
breast cancer cells?
The MKPs are a family of dual specificity phosphatases that attenuate the activity
of the MAP Kinases by dephosphorylating the threonine and tyrosine residues found in a
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TXY motif.8

MKP-1 and MKP-2 have shown the ability to dephosphorylate all three of

the MAPKs, although MKP-1 prefers to act on JNK and p38 over ERK and MKP-2 acts
primarily on ERK and JNK and not on p38.10-12 Both MKP-1 and MKP-2 are known to
be overexpressed in breast cancer,5,6,24 but to date no connection between these proteins
and breast cancer tamoxifen sensitivity has been established. MKP-1 has been previously
linked to chemotherapy resistance in a variety of cancer types, with its overexpression
leading to a decrease in JNK activity, which contributes to decreased apoptosis in cancer
cells.6 The hypothesis for this project, which states that an increase in MKP-1 protein
expression would contribute to changes in tamoxifen sensitivity via the inhibition of
JNK-mediated apoptosis, was based on this evidence.
In the research presented in this dissertation, the objectives were to: (a)
characterize MKP-1 and MKP-2 expression in breast cancer cells to begin to dissect their
contributions to tamoxifen sensitivity; (b) investigate changes in MAP Kinase activation
and correlate them to MKP expression in both tamoxifen sensitive and tamoxifen
resistant cells in order to clarify the overall picture of MAPK signaling in tamoxifen
sensitivity; and (c) to examine the promoter sequence of MKP-2 to provide insight into
its regulation in breast cancer.
MKP-1 and MKP-2 expression were found to be low in MCF7 breast cancer cells,
which are known to be tamoxifen sensitive. MCF7 cell lines overexpressing MKP-1 or
MKP-2 were generated and treated with E2, E2+TAM, TAM alone, E2+ICI or ICI alone
and it was demonstrated that MKP-1 protein expression was not altered following these
treatments, but that MKP-2 protein expression increased in response to treatment with
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anti-estrogens. Overexpressing MKP-1 decreased cell proliferation in response to E2
treatment and did not change TAM sensitivity. Western blot analysis also showed that
MKP-1 activity was directed toward ERK1/2, not JNK1/2, as JNK1/2 phosphorylation
was not observed in vector control cells. MKP-1 overexpression eliminated ERK1/2
phosphorylation compared to vector control cells. These results taken together disproved
the study hypothesis that MKP-1 contributes to changing tamoxifen sensitivity by
inhibiting JNK1/2-mediated apoptosis. However, the observation that MKP-2 protein
expression was increased following TAM treatment provided an interesting new focus for
this project.
Before beginning to study the effect of MKP-2 overexpression on tamoxifen
sensitivity, MKP expression in MCF7 and MCF7-TAMR cells was characterized. These
experiments showed that MKP-2 protein was increased in MCF7 cells following antiestrogen treatment and constitutively expressed in MCF7-TAMR cells. MKP-1 protein
expression was not detected in either cell line. MKP-2 mRNA was also shown to be
increased in MCF7-TAMR cells, while MKP-1 mRNA was undetectable. When MKP-2
was overexpressed in MCF7 cells, MTT analysis revealed that, similar to MKP-1, it
decreased cell proliferation in the presence of estrogen when compared to vehicle control
cells. MKP-2 overexpression cells were still sensitive to TAM treatment. When MKP-1
or MKP-2 protein was overexpressed in MCF7 cells and treated with E2 or the
combination of E2 and one of three increasing concentrations of tamoxifen, MTT analysis
showed that MKP-2 significantly decreased cell proliferation compared to vector control
cells. When compared to MKP-1 overexpression, MKP-2 significantly decreased cell
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proliferation across all treatment conditions, suggesting that MKP-2 overexpression
actually sensitizes cells to tamoxifen treatment. Western blot analysis showed that MKP2 was able to eliminate ERK1/2 phosphorylation.
MCF7-TAMR cells exhibited a high level of ERK1/2 activation and constitutive
expression of MKP-2 protein. These two results seem at odds with each other given that
MKP-2 overexpression seems to slow cell proliferation by dephosphorylating ERK1/2
and that these cells were sensitive to tamoxifen treatment. Previous work in our lab,
however, has shown that activated ERK1/2 is able to phosphorylate MKP-2 on Ser 386
and Ser 391, forming a feedback loop that stabilizes the protein and protects it from
proteasomal degradation.19 The working model proposes that MCF7-TAMR cells may
upregulate and stabilize MKP-2 protein in an attempt to return activated ERK1/2 to
normal cellular levels.

Even when constitutively expressed, MKP-2 is unable to

dephosphorylate all of the active ERK1/2 present in the tamoxifen resistant cells and the
drug is rendered ineffective in halting cell proliferation.
Inhibiting Raf/MEK/ERK signaling has become an attractive therapeutic strategy
in recent years and has been met with various degrees of success. Many drugs have been
developed to target EGFR activity, which is the head of the pathway, but complex
signaling networks and crosstalk between pathways also necessitate the development of
inhibitors to target downstream components of this signaling axis. One class of agents
particularly relevant to the studies presented here is MEK inhibitors. While finding a
good deal of preclinical success, only a handful of drugs have progressed beyond Phase I
clinical trials, often due to poor pharmacologic profiles81 and toxicity.82 The results
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presented here demonstrate that increasing MKP-2 expression in hormone-responsive
MCF7 cells reduced ERK1/2 activity and increased their sensitivity to tamoxifen
treatment. While increasing the expression and activity of MKP-2 itself to sensitize cells
to tamoxifen treatment is probably not a viable therapeutic strategy at this time, these
results support the importance of continuing to develop clinically effective ways to
reduce ERK1/2 activity in breast cancer cells. The idea that MKP-2 plays a role in
chemotherapy response is also supported by a recent study by Balko et al, in which
molecular profiling of basal-like breast cancer tissues revealed that loss of MKP-2
expression was associated with increased ERK1/2 pathway activation and reduced
disease-free survival following neo-adjuvant chemotherapy. The authors also suggest
that MKP-2 expression could be used as a biomarker for MEK inhibitor sensitivity in
these patients.83 In light of these results, MKP-2 might also be useful as a marker for
sensitivity in tumors that are candidates for tamoxifen treatment, although further
development of reagents that can specifically differentiate the activity and expression of
MKP-2 from MKP-1 are necessary for this strategy to be effective.
The regulation of MKP-2 gene expression in response to estrogen and tamoxifen
treatment has proven to be complex and in need of further clarification. MKP-2 promoter
analysis revealed the presence of estrogen response element half-sites, as well as
response elements for other transcription factors, such as AP-2, that are known to be
regulated by estrogen signaling.

Measurement of MKP-2-driven luciferase reporter

activity following treatment with estrogen, tamoxifen or ICI did not demonstrate any
significant change compared to vehicle control treated cells in either MCF7 or MCF7-
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TAMR cells.

This suggests that further investigation is necessary to uncover the

mechanisms responsible for regulating MKP-2 expression in response to tamoxifen
treatment.
The increased ERK signaling present in breast cancer and its connection to
tamoxifen resistance has been well documented. Much research has been done to try to
discover underlying mechanisms responsible for this activation, but less attention has
been paid to the molecules responsible for attenuating MAPK signaling, namely MKPs.
The studies presented in this dissertation characterize for the first time the expression and
activity of MKP-1 and MKP-2 in response to tamoxifen treatment and their effect on
tamoxifen sensitivity.

While this is an important advance in the MAP Kinase

Phosphatase field, further examination of the connection between MKP-2 and response to
tamoxifen is necessary to determine how this knowledge might be translated into clinical
benefit for breast cancer patients.
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The deregulation of cell signaling is a very important component in the
development and progression of cancer. One group of signaling molecules that has been
implicated in these processes is the Mitogen-Activated Protein Kinase (MAPK) family
which consists of three major branches in mammalian cells: ERK, JNK and p38. The
activity of these kinases has wide-ranging effects within the cell and must be tightly
regulated.

This is partially accomplished through the activity of Mitogen-Activated

Protein Kinase Phosphatases (MKPs). The MKPs are a family of eleven dual-specificity
threonine-tyrosine
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Increased ERK signaling has been shown to correlate with poor prognosis in
breast cancer patients and is commonly found in tumors that are resistant to tamoxifen
treatment. JNK signaling has also been shown to be increased in breast cancer tissue
samples. MKP-1 overexpression in breast cancer has been connected with resistance to a
number of different chemotherapeutic agents with the underlying mechanism being a
decrease in JNK-mediated apoptosis, but no association with tamoxifen response has
been previously studied.

These observations led to the hypothesis that MKP-1

overexpression contributes to changes in tamoxifen sensitivity via the inhibition of JNKmediated apoptosis.
The characterization of MKP-1 following its overexpression in the MCF7 cell line
revealed that its expression is not changed after tamoxifen treatment, but that the
expression of MKP-2 was increased following treatment with anti-estrogens. Both MKP1 and MKP-2 decreased cell proliferation in response to estrogen and maintained the
tamoxifen sensitivity of MCF7 cells. This decrease in proliferation was attributed to the
elimination of ERK phosphorylation, as no JNK activation was observed in these cells.
MKP-2 protein expression was shown to be constitutive in MCF7 tamoxifen resistant
cells, while MKP-1 expression was not detected. All of these results suggest that MKP-2
expression is upregulated in response to tamoxifen treatment in order to dephosphorylate
ERK and slow cell proliferation. In tamoxifen resistant cells, upregulation of MKP-2
expression is most likely an attempt to bring the high levels of ERK activation back down
to a more normal level. Its inability to do so is what allows the tamoxifen resistant
phenotype to persist.
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